

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IN04/000432

International filing date: 30 December 2004 (30.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: IN
Number: 1516/DEL/2003
Filing date: 04 January 2004 (04.01.2004)

Date of receipt at the International Bureau: 06 October 2005 (06.10.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

INV04/432



INTELLECTUAL
PROPERTY INDIA




सत्यमेव जयते

GOVERNMENT OF INDIA
MINISTRY OF COMMERCE & INDUSTRY
PATENT OFFICE, DELHI
BOUDHIK SAMPADA BHAWAN,
PLOT NO. 32, SECTOR - 14,
NEW DELHI - 110 075.

I, the undersigned being an officer duly authorized in accordance with the provision of the Patent Act, 1970 hereby certify that annexed hereto is the true copy of the Application, Provisional & Complete Specification and Drawing Sheets filed in connection with Application for Patent No.1516/Del/2003 dated 4th January 2004.

Witness my hand this 12th day of September 2005.



(P.K. PATNI)
Deputy Controller of Patents & Designs

1516 DEL 03

FORM 1

THE PATENTS ACT, 1970
(39 of 1970)

APPLICATION FOR GRANT OF A PATENT
(See sections 5(2), 7, 54 and 135 and rule 33A)

1. I/We, **NATIONAL INSTITUTE OF IMMUNOLOGY**, an Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860), Aruna Asaf Ali Marg, New Delhi 110 067, India.
2. hereby declare -
 - (a) that I am/we are in possession of an invention titled:

**IMMUNIZATION WITH RECOMBINANT ADENOVIRUS
SYNTHESIZING JAPANESE ENCEPHALITIS VIRUS ENVELOPE
PROTEIN PROTECTS MICE AGAINST LETHAL
ENCEPHALITIS**
 - (b) that the **Provisional specification** relating to this invention is filed with this application.
 - (c) that there is no lawful ground of objection to the grant of a patent to me/us.
3. Further declare that the inventor(s) for the said invention is / are :
 - (a) **SUDHANSHU VRATI** **Indian Citizen**
National Institute of Immunology
Aruna Asaf Ali Marg
New Delhi 110 067
India
4. I/We, claim the priority from the application(s) filed in convention countries, particulars of which are as follows: NIL
5. I/We, state that the said invention is an improvement in or modification of the invention, the particulars of which are as follows and of which I/We are the applicant/patentee: NA
6. I/We, state that the application is divided out of my/our application, the particulars of which are given below: 937/Del/1999
and pray that this application deemed to have been filed on June 30, 1999 under Section 16 of the Act.
7. That I am/We are the assignee or legal representative of the true and first inventors.

8. That my/our address for service in India is as follows:

K & S PARTNERS
Trademark and Patent Attorneys
84C C-6 Lane (Off Central Avenue)
Sainik Farms
New Delhi-110 062, India
Telephone: 686 5955/6533 187/6533 182
Fax : 6533889, 6518717
E-mail: kns@ndb.vsnl.net.in

9. Following declaration was given by the inventor(s) or applicant(s) in the convention country:

I/We the true and first inventors for this invention of or the applicant(s) in the convention country declare that the applicant(s) herein is/are my/our assignee or legal representative.

SUDHANSHU VRATI

10. That to the best of my/our knowledge, information and belief the fact and matters stated herein are correct and that there is no lawful ground of objection to the grant of patent to me/us on this application.

11. Following are the attachment with the application:

Provisional specification in triplicate
Drawings in triplicate
Form 3 in duplicate
Form 5
Power of Attorney [to follow]
Official fee of Rs.3000/-

I/We request that a patent may be granted to me/us for the said invention.

Dated this 4th day of December, 2003.



RAVI BHOLA
OF K & S PARTNERS
PATENT AGENT FOR THE APPLICANT

To
The Controller of Patents
Patent Office Branch
W-5, West Patent Nagar
New Delhi

1516 DEL 03
FORM 2

THE PATENTS ACT, 1970
(39 of 1970)

F 4 DEC 2002

PROVISIONAL SPECIFICATION

[See Section 10]

**IMMUNIZATION WITH RECOMBINANT ADENOVIRUS SYNTHESIZING
JAPANESE ENCEPHALITIS VIRUS ENVELOPE PROTEIN PROTECTS MICE
AGAINST LETHAL ENCEPHALITIS**

NATIONAL INSTITUTE OF IMMUNOLOGY, an Indian registered body
incorporated under the Registration of Societies Act (Act XXI of 1860), Aruna Asaf Ali
Road, New Delhi 110 067, India.

The following specification along with diagram describes the nature of this invention.

IMMUNIZATION WITH RECOMBINANT ADENOVIRUS SYNTHESIZING JAPANESE ENCEPHALITIS VIRUS ENVELOPE PROTEIN PROTECTS MICE AGAINST LETHAL ENCEPHALITIS

Filed of the invention

Japanese encephalitis virus (JEV) is a member of the *flaviviridae* family of animal viruses that consists of several viruses of immense medical significance such as those causing dengue and yellow fever. JEV, transmitted to human beings by mosquitoes, is responsible for an acute infection of the central nervous system resulting in encephalitis. The virus is active over a vast geographic area covering India, China, Japan and virtually all of South-East Asia. Approximately 3 billion people live in JEV endemic area and up to 50,000 cases of JEV infection are reported every year, of which, about 10,000 cases result in fatality and a high proportion of survivors end up having serious neurological and psychiatric sequel (49). A mouse brain-grown, formalin-inactivated JEV vaccine is available internationally. However, this vaccine has limitations in terms of its high cost of production, lack of long-term immunity and risk of allergic reaction due to the presence of the murine encephalogenic basic proteins or gelatin stabilizer (1, 36, 41, 43). There is, thus, an urgent need to develop an improved vaccine against JEV and several potential vaccines are currently being investigated in various laboratories (19).

JEV contains a single stranded, plus-sense RNA genome of ~11 Kb. It consists of a single open reading frame that codes for a large polyprotein of 3432 amino acids which is co- and post-translationally cleaved into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (5, 48). In flaviviruses, E protein is involved in a number of important functions related to virus infection such as receptor binding and membrane fusion (29). Antibodies to the E protein were shown to neutralize virus activity *in vitro* as well as *in vivo* since passive administration of monoclonal antibodies to the E protein protected mice with JEV infection (20). Furthermore, sub-viral particles consisting of only the prM and the E proteins were highly effective in generating protective immune response in mice against JEV (21, 28). Chen *et al.* (7) examined the potential of various JEV structural and non-structural proteins for vaccine development. They concluded that the E protein was the single most important protein capable of inducing protective immunity against JEV. Accordingly, several plasmid vectors have been described synthesizing different forms of JEV E protein with or without prM protein and these provided protection of varying degree in mice against Japanese encephalitis (2, 6, 18, 23).

In recent years, adenoviruses have shown great promise as a vector for recombinant vaccine development (3, 4, 8, 16, 38, 45, 46, 57). Besides being safe, these viruses have been shown to induce effective humoral and cellular immune responses in experimental animals when delivered orally, intra-muscular (IM), intra-peritoneal or intra-nasal (3, 24, 27, 44, 45, 58). In the present work, we describe construction of recombinant adenoviruses (RAds) synthesizing prM and the membrane-anchored or secretory forms of JEV E protein and report on the immunogenicity of these recombinants in mice delivered IM and orally.

Background Arts

JEV and cells. The GP78 strain of JEV was used in these studies (48). The virus was grown in neonatal mouse brain. The brain from infected mice was homogenized as a 10% suspension in Eagle's minimal essential medium (EMEM). The suspension was centrifuged and filtered through 0.22 μ M sterile filters. The virus was stored at -70°C in aliquots. Virus titration was carried out by plaque assay on porcine stable kidney (PS) monolayers as described previously (47). Adenovirus was grown in human embryonic kidney (HEK) 293A cells (Quantum Biotechnologies Inc.) cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).

Construction of recombinant adenoviruses. Recombinant adenoviruses were constructed using the Adeno-X expression system (BD Biosciences) that utilized a ligation-based strategy for producing recombinant virus. Using this system a mammalian expression cassette containing the cDNA encoding JEV E protein was incorporated into a replication incompetent (E1/ E3) human adenovirus type 5 (Ad5) genome. Two recombinant adenoviruses (RAds) were made; RAdEa, synthesizing JEV prM and the membrane-anchored E protein, and RAdEs, synthesizing prM and the secretory E protein. We have previously described plasmids pMEa and pMEs that contained the cDNAs encoding JEV prM and the membrane-anchored (Ea) or secretory E protein (Es), respectively (18). Plasmid pMEa was modified by site-directed mutagenesis to contain an *Afl* II restriction site down-stream of the 3'-end of the JEV cDNA past the *Bam* HI site. The JEV cDNA encoding the prM and Ea proteins was excised from the mutated pMEa as a *Kpn* I - *Afl* II fragment and cloned at these sites in the adenovirus shuttle plasmid pShuttle (BD Biosciences) under the control of human cytomegalovirus (CMV) immediate early (IE) promoter/enhancer to yield plasmid pSEa. The shuttle plasmid pSEa contained the bovine growth hormone (BGH) polyadenylation signal downstream

of the cloned JEV cDNA. The cDNA encoding prM and Es sequence was obtained by digesting pMEs with *Kpn* I and *Bam* HI. This cDNA fragment was ligated to the adenovirus shuttle plasmid pShuttle digested with *Kpn* I and *Hind* III at the *Kpn* I end. The free *Bam* HI and *Hind* III ends were nucleotide filled with T4 DNA polymerase and the blunt ends so created were ligated together to yield plasmid pSEs where JEV cDNA encoding prM and Es was under the control of human CMV IE promoter/enhancer. The shuttle plasmid pSEs contained the BGH polyadenylation signal downstream of the cloned cDNA. The junctions of the shuttle plasmid and the cDNA insert were sequenced to confirm the presence of the cDNA in correct frame. The plasmids pSEa and pSEs were digested with I-*Ceu* I and P1-*Sce* I to obtain the expression cassettes containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal. These were then ligated with I-*Ceu* I and P1-*Sce* I digested adenovirus plasmid pAdeno-X (BD Biosciences) to generate plasmids pAdEa and pAdEs containing the Ea and Es expression cassettes, respectively. Monolayers of HEK 293A cells were transfected with *Pac* I digested pAdEa and pAdEs using Effectene (Qiagen) and incubated for a week at 37 °C. By this time, RAD plaques had begun to show. The cell monolayers were harvested in culture supernatant, frozen-thawed thrice and centrifuged to obtain the released crude recombinant virus that was amplified once in HEK 293A cells and subjected to 2 rounds of plaque purification to obtain recombinant viruses RAdEa and RAdEs.

Radioimmunoprecipitation. Synthesis of JEV proteins by RAdEa and RAdEs was studied by infection of HEK 293A cells followed by radiolabelling and immunoprecipitation. Briefly, monolayers of HEK 293A cells were infected with virus at a multiplicity of infection (MOI) of 1 and incubated at 37 °C. After 24 hr, the cell monolayer was radiolabelled by growing in presence of 100 µCi of Easytag™ EXpre³⁵S³⁵S protein labeling mix (NEN) for 4 hr. The culture supernatant was harvested and stored at -70 °C. The monolayers were harvested in 500 µl of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM Iodoacetamide, 0.5% Triton X-100, 1% Sodium dodecyl sulphate (SDS), 1% Sodium deoxycholate, 2 mM Phenylmethylsulfonyl fluoride). Immunoprecipitation was carried out using mouse anti-JEV serum (ATCC) and Protein A Sepharose beads (Amersham). Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel that was dried before exposing to X-ray film for autoradiography.

Immunofluorescent staining. Monolayers of HEK 293A cells were infected with RAdEa, RAdEs or JEV at a MOI of 1. The cells were fixed the next day with 2% Paraformaldehyde and permeabilized with 0.1% Triton-X 100. These cells were then stained by incubation with mouse anti-JEV serum (ATCC) followed by anti-mouse IgG-FITC conjugate (Dako) and observed under a microscope using ultra-violet light.

Mice immunization and challenge experiments. All immunizations were carried out on 4-5-week-old inbred BALB/c mice. Each immunization group consisted of 6-8 mice. For IM immunizations, mice were injected in the hind legs with different amounts of RAds diluted in 100 μ l phosphate-buffered saline (PBS) using a 30G needle. Another group of mice was immunized with the mouse brain-derived, formalin-inactivated JEV vaccine manufactured by the Central Research Institute, Kasauli (India). Each mouse was given an IM injection of 100 μ l of the vaccine that was $1/10^{\text{th}}$ of the recommended adult human dose. For oral immunizations, water was withdrawn from the mice cages for 6-8 hr and then 200-400 μ l virus diluted in PBS or 100 mM Sodium bicarbonate buffer (ph 8.9) was administered per oral using a mouse-feeding needle that had a small balloon at the point of the delivery. Two booster doses, given 3 and 5 weeks after the primary immunization, contained the same amount of immunogen as the primary dose. At 44 days post-immunization, mice were challenged with intra-cerebral inoculation of the lethal dose of JEV. These mice were observed for mortality for the next 3 weeks.

Antibody assays. Titers of anti-JEV antibodies were assayed using an enzyme-linked immunosorbent assay (ELISA). An ELISA plate was coated with C6/36 cell-grown JEV overnight at 4 °C in 0.2 M Sodium carbonate buffer, pH 9.6 (39). The plate was washed with PBS containing 0.1% Tween-20 (PBS-T) thrice and the wells were blocked with 1% Lactogen in PBS-T at 37 °C for 2 hr. The plate was again washed with PBS-T thrice and incubated with 100 μ l diluted mice sera per well at 37 °C for 1 hr. Serial two-fold dilutions of sera were assayed starting at a dilution of 1:25. The plate was then washed thrice with PBS-T and 100 μ l anti-mouse antibody conjugated to horse radish peroxidase (HRP) (Dako), diluted 1:2000, was added per well, followed by incubation at 37 °C for 1 hr. The antibody-conjugate was removed by washing the plate thrice with PBS-T. The plate was then incubated in dark with 100 μ l per well of the substrate o-Phenylenediamine dihydrochloride (0.5 mg/ml) prepared in citrate buffer (1% Citric acid and 1.46% Disodium hydrogen phosphate) at room temperature for 10 min. The reaction was stopped by adding 50 μ l of 5 N Sulfuric acid. The absorbance was read at 492 nm in

an ELISA plate reader (Spectramax). The reciprocal of the highest serum dilution giving an optical density at least twice that given by the reagent blanks was taken as the ELISA end-point.

The antibody isotyping ELISAs were carried out in a similar fashion, except that in place of anti-mouse IgG-HRP conjugate, anti-mouse IgG1-HRP or the IgG2a-HRP conjugate (Pharmingen) was added. This was followed by the incubation with the substrate and color development as above.

Plaque reduction neutralization assay. Two fold serial dilutions of sera from the immunized mice (starting from 1:10) were prepared in EMEM containing 5% FCS and antibiotics. Diluted sera were incubated at 56 °C for 30 min to inactivate the complement. The serum sample (100 µl) was then mixed with equal volume of JEV culture supernatant containing 100 plaque-forming units (PFU) of the virus. The virus-antibody mixture was incubated at 37 °C for 1 hr before adding to a 35-mm dish containing ~70% confluent monolayer of PS cells. The plaque assay was carried out as described earlier (47). Percent neutralization was calculated by counting the number of plaques in the presence and the absence of the mouse serum. All assays were done in duplicates. Reciprocal of the highest serum dilution giving 50% neutralization was taken as the JEV neutralization titer.

Cytokine ELISA. Spleen cell suspensions were prepared in RPMI 1640 supplemented with 10% FCS and 6×10^7 splenocytes were incubated with 3×10^7 PFU of JEV or *E. coli*-synthesized JEV E protein (10 µg/ml) in a 35-mm dish at 37 °C. Aliquots of culture supernatant were removed every day for the next 4 days and stored at -70 °C. Interleukin (IL)-4, IL-5 and interferon (IFN)- γ were assayed using BD OptEIA kits (BD Biosciences) and as per the assay protocols.

Cytotoxic T lymphocyte (CTL) assay. Standard ^{51}Cr -release method as described previously (18) was used for the CTL assays with some modifications. Briefly, for preparation of the responder cells, 3×10^7 splenocytes were incubated for 4 days with 3×10^7 PFU of JEV in a 35-mm dish in RPMI 1640 medium supplemented with antibiotics, 0.5 mM β -Mercaptoethanol, 0.32 mg/ml L-Glutamine, 0.1 mg/ml non-essential amino acids, 0.12 mg/ml Sodium pyruvate and 5% FCS at 37 °C. The cells thus generated were referred to as the effector cells. Virus-infected target cells were prepared by infecting P388D1 cells with JEV for 48 hr at a MOI of 1 followed by incubation with 100 µCi of $\text{Na}_2^{51}\text{CrO}_4$ (NEN) and subsequent washings to remove free ^{51}Cr .

For carrying out the CTL assay, various numbers of effector cells were incubated at 37 °C for 6 hr with 2×10^4 ^{51}Cr -labelled virus-infected cells by briefly centrifuging them at 100 g for 4 min in a 96-well round bottom plate. At the end of the incubation period, 100 μl of cell-free supernatant was removed and the ^{51}Cr release was counted using a gamma counter (LKB). Triplicate estimations were done in all the assays and the percentage lysis was calculated using the following formula. Percent lysis = $[(\text{cpm released in the presence of effector cells} - \text{cpm released due to spontaneous leakage}) / (\text{total cpm released by 0.2\% Triton X-100 lysis} - \text{cpm released due to spontaneous leakage})] \times 100$.

Statistical analysis. The statistical significance of different findings between mouse groups was determined by Student's *t* test. $P \leq 0.05$ was considered to be significant.

Brief description of the accompanying drawings:

Fig.1 shows Growth of RAdS in HEK 293A cells

Fig.2 shows Synthesis of JEV proteins in HEK 293A cells infected with RAdS.

Fig.3 shows Immunofluorescent staining of virus-infected cells.

Fig.4 shows Antibody response in mice

Fig.5 shows Isotype analysis of anti-JEV antibody produced by immunized mice

Fig.6 shows JEV neutralizing antibody response in mice.

Fig.7 shows Cytokine production by splenocytes from immunized mice

Fig.8 shows CTL activity in immunized mice

Fig.9 shows Mice survival after challenge

RESULTS

Replication of RAdS and synthesis of JEV proteins. The JEV E protein is 500 amino acids long membrane-anchored protein. We have previously shown that deletion of the C-terminal 102 amino acids of JEV E protein leads to efficient secretion of the truncated protein into the cell surroundings (18). We had also shown that quality of immune responses in mice induced by the secretory E protein were different from those induced by the membrane-anchored E protein (18). Besides, vaccinia recombinants expressing the secretory E protein of Japanese encephalitis or Dengue viruses devoid of the membrane anchor sequence were found to be highly immunogenic in mice (17, 30, 40). We, therefore, constructed two recombinants, RAdEa synthesizing prM and Ea (full-

length membrane-anchored JEV E protein) and RAdEs synthesizing prM and Es (398 amino acid secretory E protein). The JEV prM was included in our constructs as its co-synthesis was necessary for correct processing and folding of the E protein (21, 28). The presence of appropriate JEV cDNA in genomes of RAds was established by polymerase chain reaction using JEV genome sequence-specific oligonucleotide primers (data not shown).

Replication of RAds was studied in HEK 293A cells infected at a MOI of 1. Figure 1 shows that a major burst in viral titers was observed both for RAdEa and RAdEs between 18 and 24 hr post-infection (PI) after which there was only a marginal increase in titers. RAdEs titer was ~40-fold higher than that of RAdEa at 24 hr PI. Following the virus replication, the cytopathic effects were first visible at 30 hr PI for both RAdEa and RAdEs. The cytopathic effects had become highly pronounced by 42 hr PI when almost 80% cells had come off the surface of the tissue culture plates. At this time point titer of RAdEs was 1.2×10^7 PFU/ml, which was 88-times higher than that of RAdEa. These results showed that compared to RAdEs, RAdEa replicated poorly in HEK 293A cells. We studied four independent isolates of RAdEa and found all them to be slow growers.

The synthesis of JEV proteins by RAds was studied in HEK 293A cells that were infected with different viruses followed by radiolabelling and immunoprecipitation of JEV proteins using mouse anti-JEV serum. Figure 2 shows that RAdEa-infected cell lysate had 2 proteins of apparent molecular masses of 51 and 23 kDa that corresponded with JEV E and prM proteins. None of these proteins were detectable in the culture supernatant of the infected cells. The RAdEs-infected cell lysate showed the synthesis of Es and prM proteins of apparent molecular masses of 45 and 23 kDa, respectively. The culture supernatant from the RAdEs-infected cells had a significant amount of Es, indicating that the E protein synthesized by RAdEs was secretory.

Use of increased amounts of anti-JEV antibody and Protein A Sepharose in immunoprecipitations did not result in precipitation of enhanced amounts of E protein indicating that the amounts of these reagents used were not limiting. Scanning of the autoradiograph with optically-enhanced densitometer using 'Diversity One' software (version 1.6, PDI, New York) followed by calculations based on the volumes of the lysate or the supernatant loaded on the gel, suggested that the secretory E protein present in the culture supernatant constituted about 76% of the total E protein synthesized by RAdEs-infected cells. Furthermore, levels of total Es protein synthesis were around 20-fold higher than the levels of Ea protein. Immunofluorescent staining of RAdEa- and RAdEs-

infected HEK 293A cells further confirmed that levels of Ea protein were significantly lower than that of the Es protein (Figure 3). The lower levels of Ea synthesis may be related to the poor growth of RAdEa in HEK 293A cells.

Anti-JEV antibody response in mice immunized with RAdS. Groups of BALB/c mice were immunized with RAdEa or RAdEs delivered orally or IM. The antibody response of these mice was compared with those immunized with formalin-inactivated commercial JEV vaccine. Serum samples collected from mice at various time points were assayed for anti-JEV end-point ELISA titers. Figure 4 shows that anti-JEV antibodies were detectable in all immunization groups on day 20 post-immunization and these titers increased further on days 28 and 44 post-immunization following the booster doses. Compared to IM immunization, antibody titers were drastically low in mice immunized orally with RAdS. For example, compared to oral immunization, 1×10^8 PFU of RAdEs given IM induced ~60-fold higher antibody response on day 44. For both the oral as well as IM immunizations, higher antibody titers were obtained when higher doses of RAd were used. No significant differences were seen in day 44 anti-JEV antibody titers of mice immunized IM with 7.5×10^5 PFU of RAdEa or RAdEs. IM immunizations with RAdS induced significantly higher antibody titers than those induced by IM inoculation of the vaccine. Thus, the lower dose of RAdEa and RAdEs (7.5×10^5 PFU) gave ~ 60-fold higher antibody titers after the second booster when compared with the titers obtained with the vaccine. At the higher dose of 1×10^8 PFU, RAdEs induced ~250-fold higher titers than the vaccine on day 44.

Some investigators have carried out oral immunization of mice with RAdS using Sodium bicarbonate buffer to neutralize the acid pH of the stomach (13, 44). However, there are others who have carried out oral immunization of mice with RAdS without the use of any buffer (3, 11, 46, 55). We have compared the immunogenicity in mice of RAdEs given orally (1×10^8 PFU) with or without the bicarbonate buffer. Figure 4 shows that no advantage was offered by the use of bicarbonate buffer during oral immunization with RAdEs. In fact, no effect of booster doses was seen when RAdEs was delivered orally using bicarbonate buffer and antibody titers on day 44 post-immunization were lower than in those mice that received the virus without bicarbonate buffer.

Isotype analyses of anti-JEV antibody produced by immunized mice. In order to analyze the quality of immune responses generated by the RAdS, end-point titers of anti-JEV IgG1 and IgG2a antibodies were determined by ELISA. Figure 5 shows that at lower dose of RAdS given orally (3×10^6 PFU) titers of anti-JEV IgG1 and IgG2a

antibodies were below 25. When a higher dose of RAdEs (1×10^8 PFU) was given orally, the majority of antibodies were of IgG1 type; the ratio of IgG1/IgG2a titers in this case was 6.48 indicating a Th2 type of immune response. When RAdEs were delivered through IM route, the anti-JEV antibody response was almost exclusively of IgG1 type. In case of mice-immunized-IM-with-RAdEa (7.5×10^5 PFU), IgG1/IgG2a titer ratio was 68 and it was 64 in the case of RAdEs (7.5×10^5 PFU)-immunized mice. At higher dose of 1×10^8 PFU, RAdEs again induced predominantly IgG1 type of anti-JEV antibodies; the ratio of IgG1/IgG2a titers in this case was 25. These results indicated that RAdEa and RAdEs induced an almost exclusive Th2 kind of immune response in mice when delivered IM. The IM immunization of mice with the vaccine also induced IgG1 dominated antibody response indicating a Th2 type immune response.

JEV neutralizing antibody response in mice immunized with RAdEs. Titers of JEV neutralizing antibodies were determined in serum samples obtained from the immunized mice at day 44 post-immunization. Figure 6 shows that oral route of immunization induced very low JEV neutralizing antibodies. Similar to ELISA titers, the JEV neutralizing antibody titers were lower in mice immunized orally with RAdEs plus the bicarbonate buffer compared to titers in those mice immunized with RAdEs without the bicarbonate buffer, although the difference was statistically insignificant. Compared to RAdEa, RAdEs given IM induced higher JEV neutralizing titers and these were enhanced further when higher dose of virus was used for immunization. IM immunization with RAdEs induced significantly higher JEV neutralizing antibody titers than those induced by the vaccine.

Cytokine secretion by splenocytes from immunized mice. Splenocytes prepared from the immunized mice were cultured in presence of JEV and synthesis of IFN- γ , IL-4 and IL-5 was studied on each day for the next 4 days. Figure 7 shows that splenocytes from mice immunize with RAdEa or RAdEs by IM route secreted large amounts of IFN- γ . Splenocytes from mice immunized with the recombinant viruses through oral route made only small amounts of IFN- γ . Similarly, mice immunized with the vaccine made only small amounts of IFN- γ . Splenocytes from IM-immunized mice also made moderate amounts of IL-5 which was almost absent in the case of orally immunized mice or mice immunized with the vaccine. IL-4 was not detectable in any of the cases; the detection limit of IL-4 ELISA was 7.8 pg/ml. Similar pattern of cytokine

secretion was observed when splenocytes were cultured in presence of JEV E protein (data not shown).

CTL activity in immunized mice. To study the generation of memory CTLs, splenocytes from immunized mice were stimulated *in vitro* with JEV and examined for cytotoxic activity against cells infected with JEV. Figure 8 shows the results of CTL assays at various effector to target cell ratios. Thus, mice immunized with RAdEa or RAdEs through IM route showed significant CTL activity. No CTL activity was detectable in mice immunized with RAdEa or RAdEs through oral route. Similarly, unimmunized and Ad5-immunized mice or those immunized with the vaccine showed no CTL activity (data not shown).

Mice challenge studies. Mice immunized with RAdS were challenged at day 44 post-immunization by intra-cerebral inoculation of a lethal dose (100 LD₅₀) of JEV. These mice were observed for mortality for 3 weeks after the challenge. All mice immunized with 7.5×10^5 or 1×10^8 PFU of RAdEs given IM survived the challenge while none of the unimmunized mice survived. Furthermore, none of the mice immunized IM or orally with 1×10^8 PFU of E1/ E3 Ad5 survived the challenge. About 50-60% protection was seen in mice immunized with 1×10^8 PFU of RAdEs given orally. The level of protection was lower (30%) when mice were immunized orally with lower doses of RAdEs (3×10^5 PFU). The level of protection afforded by RAdEa immunization was very low; about 40% mice survived from those immunized with 7.5×10^5 PFU given IM and only about 20% mice survived from the group immunized with 3×10^6 PFU given orally. In a separate experiment, 15 mice were immunized with 1×10^8 PFU of RAdEs and given 2 booster doses on day 21 and 35. When challenged on day 44 post-immunization with 1000 50% lethal doses of JEV, given intra-cerebral, 100% of the immunized mice survived.

DISCUSSION

The flavivirus E protein has been the antigen of choice for vaccine development using modern methods of vaccinology such as the DNA vaccination or the use of recombinant virus for antigen delivery (12, 14, 19, 31-34). This has been so because E protein plays an important role in a number of processes, including viral attachment, membrane fusion and entry into the host cell (29). Besides, flavivirus E protein induces virus-neutralizing antibodies and CTLs (17, 18, 25, 26, 37). It has been shown that protection against JEV is mainly antibody dependent, and virus-neutralizing antibodies alone are sufficient to impart protection (22, 35). This was also implied from our

previous observation that the formalin-inactivated JEV vaccine, which did not induce CTLs, provided protection to vaccinees against JEV (18). Thus, with a view to develop a recombinant virus-based JEV vaccine, we have constructed RAdS synthesizing JEV E protein.

During replication of JEV, the E protein is expressed on the cell surface. Plasmid DNA vectors have been described that synthesize different forms of the E protein, such as the cytoplasmic, membrane-anchored or secretory (2, 6, 7, 18, 23). These different forms of JEV E protein were shown to induce different kind of immune responses. Similarly, recombinants of vaccinia expressing the secretory E protein of Japanese encephalitis or Dengue viruses were found to be highly immunogenic in mice (17, 30, 40). Previously, we had shown that truncated JEV E protein, where the membrane-anchor sequence had been removed by deletion of the C-terminal 102 amino acids, was actively secreted in the cell surroundings (18). We have now constructed RAdS that synthesize the membrane-anchored or the secretory E protein. We found that RAdEa synthesizing the membrane-anchored E protein grew slowly and achieved 88-fold lower titers in HEK 293A cells when compared with RAdEs synthesizing the secretory E protein. Infection of HEK 293A cells with the recombinants followed by radioimmunoprecipitation of JEV proteins showed that RAdEa synthesized lower amounts of JEV E protein. This was corroborated by the low levels of immunofluorescence on RAdEa-infected HEK 293A cells when compared with RAdEs-infected cells. HEK 293A cells support replication of E1-deleted RAdS reported in this work as these cells contain Ad5 E1 transcription unit permanently integrated in them. In other mammalian cells these RAdS are unable to replicate for the want of the E1 sequences. However, expression of the foreign gene does take place, which is under the independent control of the CMV IE promoter. We have studied expression of JEV E protein by RAdS in PS cells by immunofluorescence and radioimmunoprecipitation. No significant differences were found in the levels of E protein synthesis in PS cells infected with RAdEa or RAdEs at a MOI of 1 (data not shown). The adenovirus vector used in our studies had deletions in both the E1 and E3 transcription units that allow packaging of up to 8 Kb foreign DNA in the recombinant virus. The size of JEV expression cassette inserted in RAdEa was ~3.3 Kb which was well within the packaging limits of the recombinant virus. The reason for lower titers of RAdEa in HEK 293A cells is, thus, not clear. Previously, we found no differences in the levels of expression of membrane-anchored or secretory E protein of JEV when HEK 293A cells were transfected with expression plasmids containing the Ea or Es genes

under CMV IE promoter (18). This observation together with our results in the PS cells on E protein synthesis indicates that lower levels of E protein synthesis by RAdEa in HEK 293A cells are related to the low levels of its replication.

Oral delivery of RAd has been shown to induce humoral and cellular immune responses to the protein encoded by the transgene, however, these responses have usually been weaker compared to those induced by the IM or intra-peritoneal delivery of RAd (24, 38, 46). In the present study too, oral immunization of mice by RAdS resulted in significantly lower anti-JEV antibody titers when compared with the IM route of RAd delivery. Thus, mice immunized IM with 1×10^8 PFU of RAdEs gave ~60-fold higher anti-JEV antibody response than those immunized with the same dose of the virus given orally. Use of Sodium carbonate buffer to neutralize the pH of the stomach made no perceptible difference to antibody titers when compared with the antibody titers induced by RAdEs given orally without the bicarbonate buffer. In fact, when bicarbonate buffer was used during oral immunization, the booster doses of RAdEs failed to enhance the anti-JEV antibody titers. For RAdEa too, oral delivery resulted in weaker anti-JEV antibody responses compared to the IM delivery of the recombinant. Thus, compared to oral delivery, IM inoculation of 7.5×10^5 PFU of RAdEa (which was half the dose given orally) induced ~100-fold higher anti-JEV antibody titers. The antibody titers were dose dependent. Thus higher doses of RAdEs (1×10^8 PFU) delivered orally induced higher anti-JEV antibody titers. These titers were ~4-fold higher than those induced by the commercial vaccine given IM. Importantly, IM inoculation of RAdEa or RAdEs at both the doses tested (7.5×10^5 and 1×10^8 PFU) resulted in significantly higher antibody responses than those given by the vaccine; 1×10^8 PFU of RAdEs given IM induced ~250-fold higher titer than the vaccine. Similar pattern was reflected in JEV neutralizing antibody titers when oral route of RAdS delivery was compared with the IM route although the differences weren't so pronounced. Thus ~20-fold higher JEV neutralizing antibody titers were induced by IM inoculation of 1×10^8 PFU of RAdEs compared to oral delivery of the recombinant.

Only statistically insignificant differences were noted in anti-JEV antibody titers induced by 7.5×10^5 PFU of RAdEa and RAdEs given IM. However, there was significant difference in the JEV neutralizing antibody titers generated by the two RAdS; a mean JEV neutralizing antibody titer of 10 was obtained when mice were immunized with RAdEa whereas it was 133 when mice were immunized with RAdEs. Higher JEV neutralizing antibody titers were recorded when higher doses of RAdEs were used for immunization.

At both the doses tested (7.5×10^5 and 1×10^8 PFU) IM inoculation of RAdEs induced significantly higher JEV neutralizing antibody titers than the commercial vaccine. Thus a dose of 1×10^8 PFU of RAdEs given IM induced 8-fold higher JEV neutralization titer than the vaccine. These differences in JEV neutralizing antibody titers induced by RAdEa and RAdEs by oral and IM inoculation were reflected in the level of protection afforded by these recombinants to the immunized mice against lethal JEV challenge. Thus both doses of RAdEs inducing JEV neutralizing antibody titers higher than the vaccine gave 100% protection. Immunization with RAdEs or RAdEa given orally gave only low levels of protection.

Challenge experiments indicated that mice immunized IM with the adenovirus synthesizing the membrane-anchored form of JEV E protein did not develop protective immunity whereas those immunized with recombinant synthesizing the secretory form of JEV E protein developed robust anti-JEV protective immunity resulting in 100% protection. These results show that RAd-based JEV immunizations are superior to naked DNA immunizations, which imparted only about 50-60% protection in a mouse challenge model (18). It is interesting that level of protection was similar (50-60%) when mice were immunized with plasmid DNA synthesizing Ea or Es proteins (18) whereas in the present work Es induced significantly superior protective immune response than the Ea protein. This may be related to a more efficient delivery of JEV transgene using RAd than the direct injection of naked plasmid DNA for immunization. Our finding is, however, consistent with reports from others where truncated form of JEV or Dengue E protein (leading to its secretion) was found to be more immunogenic than the membrane-anchored form of the E protein (17, 40).

Poor anti-JEV antibody induction by oral immunization with RAds was also reflected in poor cytokine secretion by splenocytes in presence of JEV. While very little IFN- γ was secreted by splenocytes from mice immunized orally with RAdEs or RAdEa, significant amounts of IFN- γ were secreted by splenocytes obtained from mice immunized IM with RAdEa or RAdEs. Splenocytes from IM immunized mice also synthesized moderate amounts of IL-5 that was not detectable in cultures of splenocytes obtained from mice immunized orally with RAds. Mice immunized IM with both RAdEa and RAdEs had significant CTL activity, which was undetectable in mice immunized orally with RAds or IM with the vaccine. Oral immunization with RAdEs at lower dose resulted in IgG1 dominated immune responses; ratio of IgG1/IgG2a end-point titers was 6.5. This is consistent with studies on oral immunization of mice with RAd synthesizing

rabies glycoprotein where abundance of anti rabies IgG1 was recorded (52). The IM inoculation of RAdEa and RAdEs also resulted in preponderance of IgG1 kind of antibodies. No data could be found in literature on antibody isotypes when adenovirus recombinants are delivered IM. Our results indicating the preponderance of IgG1 type antibodies, secretion of IFN- γ and IL-5 by splenocytes and induction of CTLs suggest that IM inoculation of mice with RAds synthesizing JEV E protein activates both the humoral and the cellular arms of the immune system, and immune responses of both Th1 and Th2 type are induced.

The results presented in this paper suggest that RAd synthesizing the secretory form of JEV E protein imparted robust immunity in mice against lethal dose of JEV given intra-cerebral. This makes RAdEs a potential candidate vaccine against JEV. Concerns have been raised in some reports about the acceptability, and thus utility, of Ad5-based recombinant vaccines in humans since a large number of adults have neutralizing antibodies to Ad5 (9, 10, 15). In recent years methods are being explored to overcome this limitation relating to the use of recombinant adenoviruses. For example, Sailaja *et al.* have demonstrated that encapsulation of recombinant Ad5 into alginate microspheres effectively circumvented the vector-specific immune responses (42). In yet another strategy, Wu *et al.* replaced the Ad5 hexon, which is the target for the neutralizing antibodies, with Ad3 hexon and such hybrid virus successfully evaded the host neutralization response to Ad5 (50). Xiang *et al.* have shown in mice that oral administration of Ad5 recombinant expressing rabies glycoprotein could successfully overcome the pre-existing immunity to the vaccine carrier (53). More recent reports from Nabel's laboratory indicate that pre-existing immunity to adenovirus could be largely overcome by priming with DNA expression vector before boosting with RAd vector (24, 56). We are now examining the utility of our JEV expression plasmid pMEs (18) for priming the mice, followed by booster with RAdEs, for immunization against JEV overcoming the pre-existing adenoviral immunity.

ACKNOWLEDGMENTS


This work was supported by the core grant given by the Department of Biotechnology, Govt. of India to the National Institute of Immunology. This work benefited from Department of Biotechnology grant nos. BT/Med/JEV/04s/02 and BT/Med/JEV/03/02.

We Claim:

1. A method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop proteins of JEV, said method comprising steps of:
 - a. digesting plasmid PMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding secretory proteins prM and Es sequences,
 - b. ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
 - c. filling nucleotides at the free *Bam* HI and *Hind* III end with T4 DNA polymerase to create blunt ends,
 - d. ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,
 - e. digesting the shuttle plasmid pSEs with restriction enzymes I-Ceu I and PI-Sce I to obtain expression cassette containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal,
 - f. ligating the digested shuttle plasmid with I-Ceu I and PI-Sce I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing Es expression cassette,
 - g. digesting the plasmid pAdEs with *Pac* I,
 - h. transfecting the monolayers HEK 293 cells with digested plasmid pAdEs for about one week, and
 - i. obtaining the recombinant virus RAdEs vaccine.
2. A method as claimed in claim 1, wherein the transfection is at about 37°C temperature
3. A method as claimed in claim 1, wherein the secretory proteins are under the control of human CMV IE promoter/enhancer.
4. A recombinant adenovirus (RAdEs) vaccine.
5. A vaccine as claimed in claim 4, wherein the vaccine produces secretory envelop proteins of JEV.
6. A vaccine as claimed in claim 4, wherein the vaccine protects against Japanese encephalitis virus (JEV) infection.
7. A vaccine as claimed in claim 4, wherein the vaccine is effective by intra-muscular route of administration.

8. A digested plasmid pAdEs of SEQ ID No. 1.
9. An effective and superior method of immunizing a subject in need thereof, to Japanese encephalitis virus (JEV) infection, said method comprising the step of administering a pharmaceutically effective amount of recombinant virus RAdEs vaccine optionally along with additive(s) to the subject intra-muscularly.
10. A method as claimed in claim 5, wherein the method shows 100% efficacy.
11. A method as claimed in claim 5, wherein the method helps protect subject against encephalitis.
12. A method as claimed in claim 5, wherein the subject is animal.
13. A method as claimed in claim 5, wherein the subject is a human being.
14. A method as claimed in claim 5, wherein the immunization activates both humoral and cell-mediated immune response.
15. A method as claimed in claim 5, wherein the humoral response to the vaccine is antibody IgG1 type.
16. A method as claimed in claim 5, wherein the method leads to high amount of secretion of IFN-gamma.
17. A method as claimed in claim 5, wherein immunization leads to moderate level secretion of IL-5.
18. A method as claimed in claim 5, wherein increase amount leads to higher immune response.
19. A method as claimed in claim 5, wherein the method is more effective than the commercially available vaccines.
20. A method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection substantially as herein described and illustrated therein.
21. A recombinant adenovirus (RAdEs) vaccine substantially as herein described and illustrated therein.

Dated this 4th day of December, 2003.


RAVI BHOLA
OF K & S PARTNERS
PATENT AGENT FOR THE APPLICANT





FIG. 1. Growth of RADs in HEK 293A cells. Monolayers of HEK 293A cells in 35-mm tissue culture dishes were infected with RADs at a MOI of 1 and incubated at 37 °C in 3 ml culture medium. At 6 hr interval the cell monolayers were lysed in the culture medium by three cycles of freeze-thawing. The cell lysate was centrifuged to remove the debris and the supernatant assayed for adenovirus titers on HEK 293A cells. Shown above are virus titers at various time points.


Ravi Bhola
of K&S Partners
Agent for the Applicant

1516-03

4 DEC 2003




FIG. 2. Synthesis of JEV proteins in HEK 293A cells infected with RAdS. HEK 293A cells were infected with JEV or RAdS at a MOI of 1. Cells were labelled 24 hr later by growth in medium containing ^{35}S -methionine and ^{35}S -cystine. After labeling, culture supernatant (CS) and cells were harvested separately. Cells were washed with PBS before the cell lysate (CL) was made. CLs and CSs were used for immunoprecipitation of JEV proteins with mouse anti-JEV serum. The proteins were separated on a 12% SDS-polyacrylamide gel and autoradiographed. Lanes containing proteins precipitated from JEV-, RAdEa- or RAdEs-infected or uninfected cells have been identified. Position of JEV proteins has been indicated at the left. Ea, Es and prM proteins synthesized by RAdS have been indicated. The values on the right are molecular size markers in kDa.

Ravi Bhola
 Ravi Bhola
 of K&S Partners
 Agent for the Applicant

1516-07

F-4 DEC 2003




FIG. 3. Immunofluorescent staining of virus-infected cells. HEK 293A cells were infected with RAdEs or JEV at a MOI of 1. The cells were fixed and permeabilized 24 hr later and stained with mouse anti-JEV serum followed by FITC-conjugated goat anti-mouse-IgG. They were then observed under a microscope using ultra-violet light. Panel A, RAdEa-infected cells; panel B, RAdEs-infected cells; panel C, JEV-infected cells and panel D, uninfected cells.

Ravi Bhola
of K&S Partners
Agent for the Applicant

1516 DEC 03
F 4 DEC 2003




FIG. 4. Antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdEs) and the routes of inoculation have been indicated below the figure. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer (pH 8.9). The primary immunization was followed by booster doses that were given 21 and 36 days later. Mice were bled at day 20, 28 and 44 post-immunization and sera stored at -70°C . Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point anti-JEV antibody titers by ELISA. Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent titers on day 20, the gray bars represent titers on day 28 and black bars show titers on day 44 post-immunization.

Ravi Bhola

Ravi Bhola
of K&S Partners
Agent for the Applicant

1516-03

4 DEC 2003




FIG. 5. Isotype analysis of anti-JEV antibody produced by immunized mice.

BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdEs) and the routes of inoculation have been indicated below the figure. The primary immunization was followed by booster doses given 21 and 36 days later. Mice sera obtained on day 44 post-immunization were assayed for the end-point ELISA titers of anti-JEV IgG1 and IgG2a antibodies. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point titers. The ELISA titer was recorded as zero if the 1:25 dilution of sample was negative in ELISA. Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent IgG1 titers and the gray bars represent IgG2a titers. The inverted triangle indicates zero mean titer.

Ravi Bhola
of K&S Partners
Agent for the Applicant

15 - 6 - 03

4 DEC 2003




FIG. 6. JEV neutralizing antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation. The dosages of the immunogens and the route of inoculation have been indicated at the top of the figure. The primary immunization was followed by booster doses given 21 and 36 days later. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer. Mice were bled on day 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:10) were assayed for end-point JEV neutralization titers by plaque reduction neutralization assays. Shown above are mean JEV neutralization titers of serum samples from immunized mice.

Ravi Bhola
of K&S Partners
Agent for the Applicant


1516 DEL 03
4 Dec 2003

FIG. 7. Cytokine production by splenocytes from immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation as indicated at the top of the figure. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV. Culture supernatants were collected each day and stored at -70°C . These were then assayed for IFN- γ , IL-4 and IL-5. Shown above are the levels of IFN- γ and IL-5 in splenocyte cultures on various days after incubation with JEV. The days are numbered at the bottom of the panel.

Ravi Bhola
Ravi Bhola
 of K&S Partners
 Agent for the Applicant

1576-03

14 DEC 2003




FIG. 8. CTL activity in immunized mice. BALB/c mice were immunized with RAdEa or RAdEs by IM route of inoculation. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV for the generation of effector cells. Shown above is the CTL activity of splenocytes at various ratios of effector cells to target cells (E : T) which are indicated at the bottom of the panels.

Ravi Bhola
of K&S Partners
Agent for the Applicant

1516-03

4 DEC 2003




FIG. 9. Mice survival after challenge. Groups of 6-8 BALB/c mice were immunized with various dosages of RAdEa and RAdEs through IM or oral route. These mice received two booster doses of the immunogen on day 22 and 36 post-immunization. Mice were challenged on day 44 post-immunization with 100 50%-lethal doses of JEV given intra-cerebrally. Mice were observed for mortality for the next three weeks. Shown above is the percentage of surviving mice at a given time point. Immunogen dose and route of inoculation have been indicated. *indicates oral delivery of RAdEs along with the bicarbonate buffer.

Ravi Bhola
 Ravi Bhola
 of K&S Partners
 Agent for the Applicant

FORM 2

THE PATENTS ACT, 1970
(39 of 1970)

COMPLETE SPECIFICATION

[See Section 10 Rule 13]

A RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS (JEV) INFECTION AND A METHOD THEREOF

We, **NATIONAL INSTITUTE OF IMMUNOLOGY**, an Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860), Aruna Asaf Ali Marg, New Delhi 110 067, India.

The following specification particularly describes and ascertains the nature of this invention and the manner in which it is to be performed.

A RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS (JEV) INFECTION AND A METHOD THEREOF

Field of the invention

The present invention relates to a method of preparing a novel recombinant adenovirus (RADEs) vaccine to protect against Japanese encephalitis virus (JEV) infection. Also, it relates to a method of immunization and to the vaccine *per se*.

Background and prior art references of the invention

Japanese encephalitis virus (JEV) is a member of the *flaviviridae* family of animal viruses that consists of several viruses of immense medical significance such as those causing dengue and yellow fever. JEV, transmitted to human beings by mosquitoes, is responsible for an acute infection of the central nervous system resulting in encephalitis. The virus is active over a vast geographic area covering India, China, Japan and virtually all of the South-East Asia. Approximately 3 billion people live in JEV endemic area and up to 50,000 cases of JEV infection are reported every year, of which, about 10,000 cases result in fatality and a high proportion of survivors end up having serious neurological and psychiatric sequel (45). A mouse brain-grown, formalin-inactivated JEV vaccine is available internationally. However, this vaccine has limitations in terms of its high cost of production, lack of long-term immunity and risk of allergic reaction due to the presence of the murine encephalogenic basic proteins or gelatin stabilizer (1, 33, 38, 39). There is, thus, an urgent need to develop an improved vaccine against JEV and several potential vaccines are currently being investigated in various laboratories (16).

JEV contains a single-stranded, plus-sense RNA genome of ~11 Kb. It consists of a single open reading frame that codes for a large polyprotein of 3432 amino acids which is co- and post-translationally cleaved into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (5, 44). In flaviviruses, E protein is involved in a number of important functions related to virus infection such as receptor binding and membrane fusion (26). Antibodies to the E protein were shown to neutralize virus activity *in vitro* as well as *in vivo* since passive administration of monoclonal antibodies to the E protein protected mice with JEV infection (17). Furthermore, sub-viral particles consisting of only the prM and the E proteins were highly effective in generating protective immune response in mice against JEV (18, 25). Chen *et al.* (7) examined the potential of

various JEV structural and non-structural proteins for vaccine development. They concluded that the E protein was the single most important protein capable of inducing protective immunity against JEV. Accordingly, several plasmid vectors have been described synthesizing different forms of JEV E protein with or without prM protein and these provided protection of varying degree in mice against Japanese encephalitis (2, 6, 15, 20).

In recent years, adenoviruses have shown great promise as vectors for recombinant vaccine development (3, 4, 8, 13, 35, 41, 42, 49). Besides being safe, these viruses have been shown to induce effective humoral and cellular immune responses in experimental animals when delivered orally, intra-muscular (IM), intra-peritoneal or intra-nasal (3, 21, 24, 40, 41, 50). In the present invention, we constructed RAdEa expressing the prM and the full length JEV E protein since it is known to induce neutralizing immune response. However, adenovirus recombinant (RAdEa) synthesizing the full-length protein (Ea) did not grow well. Besides it induced poor immune response and very little JEV neutralizing antibodies. The full-length E protein is membrane anchored and removing the anchor signal from it is likely to make it soluble and perhaps more immunogenic.

On this premise, we truncated the Ea protein to remove 102-amino acid hydrophobic sequence from the C-terminus of the protein to generate a 398-amino acid Es protein. Recombinant adenovirus RAdEs synthesizing JEV prM and Es was found to grow very well in cultured cells and synthesize JEV E protein that was secreted into the medium. So, the removal of 102-amino acid hydrophobic sequence from the C-terminus of the protein played a critical role in smooth culturing of the recombinant. Even the inventors were pleasantly surprised with this effect.

Further, this recombinant adenovirus, synthesizing a novel form of JEV E protein that was secretory as opposed to the anchored protein in the normal course, was highly immunogenic in mice. RAdEs induced high titers of JEV neutralizing antibodies and protected the immunized mice against lethal JEV challenge demonstrating its potential use as a vaccine against JEV infection. The highly immunogenic effect of the recombinant helped achieve the desired results, which were long awaited by the scientific community.

The infection caused by JEV is fatal in nature and absence of long-term immunity had added to the problem. The allergic reactions to the known vaccine had further

compounded the problem. However, administration of the vaccine of instant invention is been found to be absolutely safe and free from adverse effects.

Objects of the invention

The main object of the present invention is to develop a recombinant adenovirus (RAdEs) vaccine against JEV infection.

Another main object of the present invention is to develop an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection.

Yet another object of the present invention is to develop a plasmid pAdEs of SEQ ID No. 1.

Still another object of the present invention is to develop a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection.

Summary of the invention

The present invention relates to development of a novel recombinant adenovirus (RAdEs) vaccine against Japanese encephalitis virus (JEV) infection.

Detailed description of the invention

Accordingly, the present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a plasmid pAdEs of SEQ ID No. 1; and lastly, a method of preparing the recombinant adenovirus (RAdEs) vaccine.

In the main embodiment of the present invention, it relates to a method of preparing a recombinant adenovirus (RAdEs) vaccine – the Accession No.04121701, deposited at European Collection of Animal Cell Cultures, Salisbury, United Kingdom, to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein of JEV, said method comprising steps of:

- digesting plasmid pMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding JEV proteins prM and Es,
- ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
- filling nucleotides at the free *Bam* HI and *Hind* III ends with T4 DNA polymerase to create blunt ends,
- ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,

- digesting the shuttle plasmid pSEs with restriction enzymes *I-Ceu* I and *Pi-Sce* I to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
- ligating the digested shuttle plasmid with *I-Ceu* I and *Pi-Sce* I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing the Es expression cassette,
- digesting the plasmid pAdEs with *Pac* I,
- transfecting the monolayers of HEK 293 cells with digested plasmid pAdEs for about one week, and
- obtaining the recombinant virus RAdEs vaccine. The Accession Number 04121701 deposited at European Collection of Animal Cell Cultures, Salisbury, United Kingdom.

In another embodiment of the present invention, the transfection is at about 37°C temperature.

In yet another embodiment of the present invention, the secretory proteins are under the control of human CMV IE promoter/enhancer.

In another main embodiment of the present invention, the invention relates to a recombinant adenovirus (RAdEs) vaccine. The Accession Number 04121701 deposited at European Collection of Animal Cell Cultures, Salisbury, United Kingdom.

In yet another embodiment of the present invention, the vaccine produces secretory envelop protein (Es) of JEV.

In still another embodiment of the present invention, the vaccine protects against Japanese encephalitis virus (JEV) infection.

In still another embodiment of the present invention, the vaccine is effective by intra-muscular route of administration.

In another main embodiment of the present invention, the invention relates to a plasmid pAdEs of SEQ ID No. 1.

In another main embodiment of the present invention, the invention relates to an effective and superior method of immunizing a subject in need thereof, to Japanese encephalitis virus (JEV) infection, said method comprising the step of administering a pharmaceutically effective amount of recombinant virus RAdEs vaccine. The Accession Number 04121701 deposited at European Collection of Animal Cell Cultures, Salisbury, United Kingdom, optionally along with additive(s) to the subject intra-muscularly.

In yet another embodiment of the present invention, the method shows 100% efficacy.

In still another embodiment of the present invention, the method helps protect subject against Japanese encephalitis.

In still another embodiment of the present invention, the subject is animal.

In still another embodiment of the present invention, the subject is a human being.

In still another embodiment of the present invention, the immunization activates both humoral and cell-mediated immune responses.

In still another embodiment of the present invention, the humoral response to the vaccine is antibody IgG1 type.

In still another embodiment of the present invention, the method leads to high amount of IFN-gamma secretion.

In still another embodiment of the present invention, the immunization leads to IL-5 secretion at moderate levels.

In still another embodiment of the present invention, increased amounts of RAdEs lead to higher immune response.

In still another embodiment of the present invention, the method is more effective than the commercially available vaccine.

Replication-defective recombinant adenoviruses (RAds) were constructed that synthesized the pre-Membrane (prM) and envelope (E) proteins of Japanese encephalitis virus (JEV). Recombinant virus RAdEa synthesized Ea, the membrane-anchored form of the E protein, and RAdEs synthesized Es, the secretory E protein.

RAdEa replicated poorly in human embryonic kidney (HEK) 293A cells and 88-folds lower titers of the virus were obtained compared to RAdEs. RAdEa also synthesized lower amounts of E protein in HEK 293A cells as judged by radioimmunoprecipitation and immunofluorescence studies.

Mice were immunized intra-muscular (IM) and orally with RAds. Oral route of virus delivery induced low titers of anti-JEV antibodies that had only little JEV neutralizing activity. IM immunizations with both RAdEa and RAdEs resulted in high titers of anti-JEV antibodies. Interestingly, RAdEa induced very low titers of JEV neutralizing antibodies whereas RAdEs inoculation resulted in high titers of JEV neutralizing antibodies. Splenocytes from mice immunized IM with RAds secreted large amounts of interferon- γ and moderate amounts of interleukin-5. These splenocytes also showed cytotoxic activity against JEV-infected cells. Mice immunized IM with RAdEs showed complete protection against the lethal dose of JEV given intra-cerebral.

Brief description of the accompanying drawings:

Fig. 1 shows Growth of RAdS in HEK 293A cells. Monolayers of HEK 293A cells in 35-mm tissue culture dishes were infected with RAdS at a multiplicity of infection (MOI) of 1 and incubated at 37 °C in 3 ml culture medium. At 6 hr interval the cell monolayers were lysed in the culture medium by three cycles of freeze-thawing. The cell lysate was centrifuged to remove the debris and the supernatant assayed for adenovirus titers on HEK 293A cells. Shown in the figure are virus titers at various time points.

Fig. 2 shows Synthesis of JEV proteins in HEK 293A cells infected with RAdS. HEK 293A cells were infected with JEV or RAdS at a MOI of 1. Cells were labelled 24 hr later by growth in medium containing ³⁵S-methionine and ³⁵S-cystine. After labeling, culture supernatant (CS) and cells were harvested separately. Cells were washed with PBS before the cell lysate (CL) was made. CLs and CSs were used for immunoprecipitation of JEV proteins with mouse anti-JEV serum. The proteins were separated on a 12% SDS-polyacrylamide gel and autoradiographed. Lanes containing proteins precipitated from JEV-, RAdEa- or RAdEs-infected or uninfected cells have been identified. Position of JEV proteins has been indicated at the left. Ea, Es and prM proteins synthesized by RAdS have been indicated. The values on the right are molecular size markers in kDa.

Fig. 3 shows Immunofluorescent staining of virus-infected cells. HEK 293A cells were infected with RAdS or JEV at a MOI of 1. The cells were fixed and permeabilized 24 hr later and stained with mouse anti-JEV serum followed by FITC-conjugated goat anti-mouse-IgG. They were then observed under a microscope using ultra-violet light. Panel A, RAdEa-infected cells; panel B, RAdEs-infected cells; panel C, JEV-infected cells and panel D, uninfected cells.

Fig. 4 shows Antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdS) and the routes of inoculation have been indicated below the figure. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer (pH 8.9). The primary immunization was followed by booster doses that were given 21 and 36 days later. Mice were bled at day 20, 28 and 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point anti-JEV antibody titers by ELISA.

Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent titers on day 20, the gray bars represent titers on day 28 and black bars show titers on day 44 post-immunization.

Fig. 5 shows Isotype analysis of anti-JEV antibody produced by immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdS) and the routes of inoculation have been indicated below the figure. The primary immunization was followed by booster doses given 21 and 36 days later. Mice sera obtained on day 44 post-immunization were assayed for the end-point ELISA titers of anti-JEV IgG1 and IgG2a antibodies. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point titers. The ELISA titer was recorded as zero if the 1:25 dilution of sample was negative in ELISA. Shown in the figure are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent IgG1 titers and the gray bars represent IgG2a titers. The inverted triangle indicates zero mean titer.

Fig. 6 shows JEV neutralizing antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation. The dosages of the immunogens and the route of inoculation have been indicated at the top of the figure. The primary immunization was followed by booster doses given 21 and 36 days later. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer. Mice were bled on day 44 post-immunization and sera stored at -70°C . Serial two-fold dilutions of sera (starting at 1:10) were assayed for end-point JEV neutralization titers by plaque reduction neutralization assays. Shown in the figure are mean JEV neutralization titers of serum samples from immunized mice.

Fig. 7 shows Cytokine production by splenocytes from immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation as indicated at the top of the figure. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV. Culture supernatants were collected each day and stored at -70°C . These were then assayed for IFN- γ , IL-4 and IL-5. Shown in the figure are the levels of IFN- γ and IL-5 in splenocyte cultures on various days after incubation with JEV. The days are numbered at the bottom of the panel.

Fig. 8 shows CTL activity in immunized mice. BALB/c mice were immunized with RAdEa or RAdEs by IM route of inoculation. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV for the generation of effector cells. Shown in the figure is the CTL activity of splenocytes at various ratios of effector cells to target cells (E : T) which are indicated at the bottom of the panels.

Fig. 9 shows Mice survival after challenge. Groups of 6-8 BALB/c mice were immunized with various dosages of RAdEa and RAdEs through IM or oral route. These mice received two booster doses of the immunogen on day 22 and 36 post-immunization. Mice were challenged on day 44 post-immunization with 100 LD₅₀ (50%-lethal dose) of JEV given intra-cerebrally. Mice were observed for mortality for the next three weeks. Shown above is the percentage of surviving mice at a given time point. Immunogen dose and route of inoculation have been indicated. *indicates oral delivery of RAdEs along with the bicarbonate buffer.

The invention is further elaborated with the help of experimental data, as presented below in the form of examples. However, the examples should not be construed to limit the scope of the invention

Example – 1

JEV and cells: The GP78 strain of JEV was used in these studies (44). The virus was grown in neonatal mouse brain. The brain from infected mice was homogenized as a 10% suspension in Eagle's minimal essential medium (EMEM). The suspension was centrifuged and filtered through 0.22 µm sterile filters. The virus was stored at -70 °C in aliquots. Virus titration was carried out by plaque assay on porcine stable kidney (PS) monolayers as described previously (43). Adenovirus was grown in human embryonic kidney (HEK) 293A cells (Quantum Biotechnologies Inc.) cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).

Example – 2

Construction of recombinant adenoviruses: Recombinant adenoviruses were constructed using the Adeno-X expression system (BD Biosciences) that utilized a ligation-based strategy for producing recombinant virus. Using this system a mammalian expression cassette containing the cDNA encoding JEV E protein was

incorporated into a replication incompetent (E1/ E3) human adenovirus type 5 (Ad5) genome. Two recombinant adenoviruses (RAds) were made; RAdEa, synthesizing JEV prM and the membrane-anchored E protein, and RAdEs, synthesizing prM and the secretory E protein. Plasmids pMEa and pMEs that contained the cDNAs encoding JEV prM and the membrane-anchored (Ea) or secretory E protein (Es), respectively have been described previously (15). Plasmid pMEa was modified by site-directed mutagenesis to contain an *Afl* II restriction site down-stream of the 3'-end of the JEV cDNA past the *Bam* HI site. The JEV cDNA encoding the prM and Ea proteins was excised from the mutated pMEa as a *Kpn* I - *Afl* II fragment and cloned at these sites in the adenovirus shuttle plasmid pShuttle (BD Biosciences) under the control of human cytomegalovirus (CMV) immediate early (IE) promoter/enhancer to yield plasmid pSEa. The shuttle plasmid pSEa contained the bovine growth hormone (BGH) polyadenylation signal downstream of the cloned JEV cDNA. The cDNA encoding prM and Es sequence was obtained by digesting pMEs with *Kpn* I and *Bam* HI. This cDNA fragment was ligated to the adenovirus shuttle plasmid, pShuttle, digested with *Kpn* I and *Hind* III at the *Kpn* I end. The free *Bam* HI and *Hind* III ends were nucleotide filled with T4 DNA polymerase and the blunt ends so created were ligated together to yield plasmid pSEs where JEV cDNA encoding prM and Es was under the control of human CMV IE promoter/enhancer. The shuttle plasmid pSEs contained the BGH polyadenylation signal downstream of the cloned cDNA. The junctions of the shuttle plasmid and the cDNA insert were sequenced to confirm the presence of the cDNA in correct frame. The plasmids pSEa and pSEs were digested with *I-Ceu* I and *P1-Sce* I to obtain the expression cassettes containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal. These were then ligated with *I-Ceu* I and *P1-Sce* I digested adenovirus plasmid pAdeno-X (BD Biosciences) to generate plasmids pAdEa and pAdEs containing the Ea and Es expression cassettes, respectively. Monolayers of HEK 293A cells were transfected with *Pac* I digested pAdEa and pAdEs using Effectene (Qiagen) and incubated for a week at 37 °C. By this time, RAd plaques had begun to show. The cell monolayers were harvested in culture supernatant, frozen-thawed thrice and centrifuged to obtain the released crude recombinant virus that was amplified once in HEK 293A cells and subjected to 2 rounds of plaque purification to obtain recombinant viruses RAdEa and RAdEs.

Example - 3

Radioimmunoprecipitation: Synthesis of JEV proteins by RAdEa and RAdEs was studied by infection of HEK 293A cells followed by radiolabelling and immunoprecipitation. Briefly, monolayers of HEK 293A cells were infected with virus at a multiplicity of infection (MOI) of 1 and incubated at 37 °C. After 24 hr, the cell monolayer was radiolabelled by growing in presence of 100 µCi of Easytag™ EXpre³⁵S³⁵S protein labeling mix (NEN) for 4 hr. The culture supernatant was harvested and stored at -70 °C. The monolayers were harvested in 500 µl of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM Iodoacetamide, 0.5% Triton X-100, 1% Sodium dodecyl sulphate (SDS), 1% Sodium deoxycholate, 2 mM Phenylmethylsulfonyl fluoride). Immunoprecipitation was carried out using mouse anti-JEV serum (ATCC) and Protein A Sepharose beads (Amersham). Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel that was dried before exposing to X-ray film for autoradiography.

Example - 4

Immunofluorescent staining: Monolayers of HEK 293A cells were infected with RAdEa, RAdEs or JEV at a MOI of 1. The cells were fixed the next day with 2% Paraformaldehyde and permeabilized with 0.1% Triton-X 100. These cells were then stained by incubation with mouse anti-JEV serum (ATCC) followed by anti-mouse IgG-FITC conjugate (Dako) and observed under a microscope using ultra-violet light.

Example - 5

Mice immunization and challenge experiments: All immunizations were carried out on 4-5-week-old inbred BALB/c mice. Each immunization group consisted of 6-8 mice. For IM immunizations, mice were injected in the hind legs with different amounts of RAds diluted in 100 µl phosphate-buffered saline (PBS) using a 30G needle. Another group of mice was immunized with the mouse brain-derived, formalin-inactivated JEV vaccine manufactured by the Central Research Institute, Kasauli (India). Each mouse was given an IM injection of 100 µl of the vaccine that was 1/10th of the recommended adult human dose. For oral immunizations, water was withdrawn from the mice cages for 6-8 hr and then 200-400 µl virus diluted in PBS or 100 mM Sodium bicarbonate buffer (ph 8.9) was administered per oral using a mouse-feeding needle that had a small balloon at the point of the delivery. Two booster doses, given 3 and 5 weeks after the primary immunization, contained the same amount of

immunogen as the primary dose. At 44 days post-immunization, mice were challenged with intra-cerebral inoculation of the lethal dose of JEV. These mice were observed for mortality for the next 3 weeks.

Example - 6

Antibody assays: Titers of anti-JEV antibodies were assayed using an enzyme-linked immunosorbent assay (ELISA). An ELISA plate was coated with C6/36 cell-grown JEV overnight at 4 °C in 0.2 M Sodium carbonate buffer, pH 9.6 (36). The plate was washed with PBS containing 0.1% Tween-20 (PBS-T) thrice and the wells were blocked with 1% Lactogen in PBS-T at 37 °C for 2 hr. The plate was again washed with PBS-T thrice and incubated with 100 µl diluted mice sera per well at 37 °C for 1 hr. Serial two-fold dilutions of sera were assayed starting at a dilution of 1:25. The plate was then washed thrice with PBS-T and 100-µl anti-mouse antibody conjugated to horse radish peroxidase (HRP) (Dako), diluted 1:2000, was added per well, followed by incubation at 37 °C for 1 hr. The antibody-conjugate was removed by washing the plate thrice with PBS-T. The plate was then incubated in dark with 100 µl per well of the substrate o-Phenylenediamine dihydrochloride (0.5 mg/ml) prepared in citrate buffer (1% Citric acid and 1.46% Disodium hydrogen phosphate) at room temperature for 10 min. The reaction was stopped by adding 50 µl of 5 N Sulfuric acid. The absorbance was read at 492 nm in an ELISA plate reader (Spectramax). The reciprocal of the highest serum dilution giving an optical density at least twice that given by the reagent blanks was taken as the ELISA end-point.

The antibody isotyping ELISAs were carried out in a similar fashion, except that in place of anti-mouse IgG-HRP conjugate, anti-mouse IgG1-HRP or the IgG2a-HRP conjugate (Pharmingen) was added. This was followed by the incubation with the substrate and color development as above.

Example - 7

Plaque reduction neutralization assay: Two fold serial dilutions of sera from the immunized mice (starting from 1:10) were prepared in EMEM containing 5% FCS and antibiotics. Diluted sera were incubated at 56 °C for 30 min to inactivate the complement. The serum sample (100 µl) was then mixed with equal volume of JEV culture supernatant containing 100 plaque-forming units (PFU) of the virus. The virus-antibody mixture was incubated at 37 °C for 1 hr before adding to a 35-mm dish containing ~70% confluent monolayer of PS cells. The plaque assay was carried out as

described (43). Percent neutralization was calculated by counting the number of plaques in the presence and the absence of the mouse serum. All assays were done in duplicates. Reciprocal of the highest serum dilution giving 50% neutralization was taken as the JEV neutralization titer.

Example – 8

Cytokine ELISA: Spleen cell suspensions were prepared in RPMI 1640 supplemented with 10% FCS and 6×10^7 splenocytes were incubated with 3×10^7 PFU of JEV or *E. coli*-synthesized JEV E protein (10 $\mu\text{g/ml}$) in a 35-mm dish at 37 °C. Aliquots of culture supernatant were removed every day for the next 4 days and stored at -70 °C. Interleukin (IL)-4, IL-5 and interferon (IFN)- γ were assayed using BD OptEIA kits (BD Biosciences) and as per the assay protocols.

Example – 9

Cytotoxic T lymphocyte (CTL) assay: Standard ^{51}Cr -release method as described previously (15) was used for the CTL assays with some modifications. Briefly, for preparation of the responder cells, 3×10^7 splenocytes were incubated for 4 days with 3×10^7 PFU of JEV in a 35-mm dish in RPMI 1640 medium supplemented with antibiotics, 0.5 mM β -Mercaptoethanol, 0.32 mg/ml L-Glutamine, 0.1 mg/ml non-essential amino acids, 0.12 mg/ml Sodium pyruvate and 5% FCS at 37 °C. The cells thus generated were referred to as the effector cells. Virus-infected target cells were prepared by infecting P388D1 cells with JEV for 48 hr at a MOI of 1 followed by incubation with 100 μCi of $\text{Na}_2^{51}\text{CrO}_4$ (NEN) and subsequent washings to remove free ^{51}Cr .

For carrying out the CTL assay, various numbers of effector cells were incubated at 37°C for 6 hr with 2×10^4 ^{51}Cr -labelled virus-infected cells by briefly centrifuging them at 100 g for 4 min in a 96-well round bottom plate. At the end of the incubation period, 100 μl of cell-free supernatant was removed and the ^{51}Cr release was counted using a gamma counter (LKB). Triplicate estimations were done in all the assays and the percentage lysis was calculated using the following formula. Percent lysis = [(cpm released in the presence of effector cells – cpm released due to spontaneous leakage)/(total cpm released by 0.2% Triton X-100 lysis – cpm released due to spontaneous leakage)] x 100.

Statistical analysis: The statistical significance of different findings between mouse groups was determined by Student's *t* test. $P \leq 0.05$ was considered to be significant.

Example – 10

Replication of RAds and synthesis of JEV proteins: The JEV E protein is 500 amino acids long membrane-anchored protein. We have earlier shown that deletion of the C-terminal 102 amino acids of JEV E protein leads to efficient secretion of the truncated protein into the cell surroundings (15). We had also shown that quality of immune responses in mice induced by the secretory E protein were different from those induced by the membrane-anchored E protein (15). Besides, vaccinia recombinants expressing the secretory E protein of Japanese encephalitis or Dengue viruses devoid of the membrane anchor sequence were found to be highly immunogenic in mice (14, 27, 37). We, therefore, constructed two recombinants, RAdEa synthesizing prM and Ea (full-length membrane-anchored JEV E protein) and RAdEs synthesizing prM and Es (398 amino acid secretory E protein). The JEV prM was included in our constructs as its co-synthesis was necessary for correct processing and folding of the E protein (18, 25). The presence of appropriate JEV cDNA in genomes of RAds was established by polymerase chain reaction using JEV genome sequence-specific oligonucleotide primers.

Replication of RAds was studied in HEK 293A cells infected at a MOI of 1. Figure 1 shows that a major burst in viral titers was observed both for RAdEa and RAdEs between 18 and 24 hr post-infection (PI) after which there was only a marginal increase in titers. RAdEs titer was ~40-fold higher than that of RAdEa at 24 hr PI. Following the virus replication, the cytopathic effects were first visible at 30 hr PI for both RAdEa and RAdEs. The cytopathic effects had become highly pronounced by 42 hr PI when almost 80% cells had come off the surface of the tissue culture plates. At this time point titer of RAdEs was 1.2×10^7 PFU/ml, which was 88-times higher than that of RAdEa. These results showed that compared to RAdEs, RAdEa replicated poorly in HEK 293A cells. We studied four independent isolates of RAdEa and found all them to be slow growers.

The synthesis of JEV proteins by RAds was studied in HEK 293A cells that were infected with different viruses followed by radiolabelling and immunoprecipitation of JEV proteins using mouse anti-JEV serum. Figure 2 shows that RAdEa-infected cell lysate had 2 proteins of apparent molecular masses of 51 and 23 kDa that corresponded with JEV E and prM proteins. None of these proteins were detectable in the culture supernatant of the infected cells. The RAdEs-infected cell lysate showed the synthesis

of Es and prM proteins of apparent molecular masses of 45 and 23 kDa, respectively. The culture supernatant from the RAdEs-infected cells had a significant amount of Es, indicating that the E protein synthesized by RAdEs was secretory.

Use of increased amounts of anti-JEV antibody and Protein A Sepharose in immunoprecipitations did not result in precipitation of enhanced amounts of E protein indicating that the amounts of these reagents used were not limiting. Scanning of the autoradiograph with optically-enhanced densitometer using 'Diversity One' software (version 1.6, PDI, New York) followed by calculations based on the volumes of the lysate or the supernatant loaded on the gel, suggested that the secretory E protein present in the culture supernatant constituted about 76% of the total E protein synthesized by RAdEs-infected cells. Furthermore, levels of total Es protein synthesis were around 20-fold higher than the levels of Ea protein. Immunofluorescent staining of RAdEa- and RAdEs-infected HEK 293A cells further confirmed that levels of Ea protein were significantly lower than that of the Es protein (Figure 3). The lower levels of Ea synthesis may be related to the poor growth of RAdEa in HEK 293A cells.

We found that RAdEa synthesizing the membrane-anchored E protein grew slowly and achieved 88-fold lower titers in HEK 293A cells when compared with RAdEs synthesizing the secretory E protein. Infection of HEK 293A cells with the recombinants followed by radioimmunoprecipitation of JEV proteins showed that RAdEa synthesized lower amounts of JEV E protein. This was corroborated by the low levels of immunofluorescence on RAdEa-infected HEK 293A cells when compared with RAdEs-infected cells. HEK 293A cells support replication of E1-deleted RAds reported in this work as these cells contain Ad5 E1 transcription unit permanently integrated in them. In other mammalian cells these RAds are unable to replicate for the want of the E1 sequences. However, expression of the foreign gene does take place, which is under the independent control of the CMV IE promoter. We have studied expression of JEV E protein by RAds in PS cells by immunofluorescence and radioimmunoprecipitation. No significant differences were found in the levels of E protein synthesis in PS cells infected with RAdEa or RAdEs at a MOI of 1.

The adenovirus vector used in our studies had deletions in both the E1 and E3 transcription units that allow packaging of up to 8 Kb foreign DNA in the recombinant virus. The size of JEV expression cassette inserted in RAdEa was ~3.3 Kb which was well within the packaging limits of the recombinant virus. The reason for lower titers of

RADEa in HEK 293A cells is, thus, not clear. Previously, we found no differences in the levels of expression of membrane-anchored or secretory E protein of JEV when HEK 293A cells were transfected with expression plasmids containing the Ea or Es genes under CMV-IE promoter (15). This observation together with our results in the PS cells on E protein synthesis indicates that lower levels of E protein synthesis by RADEa in HEK 293A cells are related to the low levels of its replication.

Example - 11

Anti-JEV antibody response in mice immunized with RAdS: Groups of BALB/c mice were immunized with RADEa or RAdEs delivered orally or IM. The antibody response of these mice was compared with those immunized with formalin-inactivated commercial JEV vaccine. Serum samples collected from mice at various time points were assayed for anti-JEV end-point ELISA titers. Figure 4 shows that anti-JEV antibodies were detectable in all immunization groups on day 20 post-immunization and these titers increased further on days 28 and 44 post-immunization following the booster doses. Compared to IM immunization, antibody titers were drastically low in mice immunized orally with RAdS. For example, compared to oral immunization, 1×10^8 PFU of RAdEs given IM induced ~60-fold higher antibody response on day 44. For both the oral as well as IM immunizations, higher antibody titers were obtained when higher doses of RAd were used. No significant differences were seen in day 44 anti-JEV antibody titers of mice immunized IM with 7.5×10^5 PFU of RADEa or RAdEs. IM immunizations with RAdS induced significantly higher antibody titers than those induced by IM inoculation of the vaccine. Thus, the lower dose of RADEa and RAdEs (7.5×10^5 PFU) gave ~ 60-fold higher antibody titers after the second booster when compared with the titers obtained with the vaccine. At the higher dose of 1×10^8 PFU, RAdEs induced ~250-fold higher titers than the vaccine on day 44.

Some investigators have carried out oral immunization of mice with RAdS using Sodium bicarbonate buffer to neutralize the acid pH of the stomach (11, 40, 47). However, there are others who have carried out oral immunization of mice with RAdS without the use of any buffer (3, 9, 42, 48). We have compared the immunogenicity in mice of RAdEs given orally (1×10^8 PFU) with or without the bicarbonate buffer. Figure 4 shows that no advantage was offered by the use of bicarbonate buffer during oral immunization with RAdEs. In fact, no effect of booster doses was seen when RAdEs was delivered orally using bicarbonate buffer and antibody titers on day 44

post-immunization were lower than in those mice that received the virus without bicarbonate buffer.

Example - 12

Isotype analyses of anti-JEV antibody produced by immunized mice: In order to analyze the quality of immune responses generated by the RAdS, end-point titers of anti-JEV IgG1 and IgG2a antibodies were determined by ELISA. Figure 5 shows that at lower dose of RAdS given orally (3×10^6 PFU) titers of anti-JEV IgG1 and IgG2a antibodies were below 25. When a higher dose of RAdEs (1×10^8 PFU) was given orally, the majority of antibodies were of IgG1 type; the ratio of IgG1/IgG2a titers in this case was 6.48 indicating a Th2 type of immune response. When RAdS were delivered through IM route, the anti-JEV antibody response was almost exclusively of IgG1 type. In case of mice immunized IM with RAdEa (7.5×10^5 PFU), IgG1/IgG2a titer ratio was 68 and it was 64 in the case of RAdEs (7.5×10^5 PFU)-immunized mice. At higher dose of 1×10^8 PFU, RAdEs again induced predominantly IgG1 type of anti-JEV antibodies; the ratio of IgG1/IgG2a titers in this case was 25. These results indicated that RAdEa and RAdEs induced an almost exclusive Th2 kind of immune response in mice when delivered IM. The IM immunization of mice with the vaccine also induced IgG1 dominated antibody response indicating a Th2 type immune response.

Example - 13

JEV neutralizing antibody response in mice immunized with Rads: Titers of JEV neutralizing antibodies were determined in serum samples obtained from the immunized mice at day 44 post-immunization. Figure 6 shows that oral route of immunization induced very low JEV neutralizing antibodies. Similar to ELISA titers, the JEV neutralizing antibody titers were lower in mice immunized orally with RAdEs plus the bicarbonate buffer compared to titers in those mice immunized with RAdEs without the bicarbonate buffer, although the difference was statistically insignificant. Compared to RAdEa, RAdEs given IM induced higher JEV neutralizing titers and these were enhanced further when higher dose of virus was used for immunization. IM immunization with RAdEs induced significantly higher JEV neutralizing antibody titers than those induced by the vaccine.

Example – 14

Cytokine secretion by splenocytes from immunized mice: Splenocytes prepared from the immunized mice were cultured in presence of JEV and synthesis of IFN- γ , IL-4 and IL-5 was studied on each day for the next 4 days. Figure 7 shows that splenocytes from mice immunized with RAdEa or RAdEs by IM route secreted large amounts of IFN- γ . Splenocytes from mice immunized with the recombinant viruses through oral route made only small amounts of IFN- γ . Similarly, mice immunized with the vaccine made only small amounts of IFN- γ . Splenocytes from IM-immunized mice also made moderate amounts of IL-5 which was almost absent in the case of orally immunized mice or mice immunized with the vaccine. IL-4 was not detectable in any of the cases; the detection limit of IL-4 ELISA was 7.8 pg/ml. Similar pattern of cytokine secretion was observed when splenocytes were cultured in presence of JEV E protein

Example – 15

CTL activity in immunized mice: To study the generation of memory CTLs, splenocytes from immunized mice were stimulated *in vitro* with JEV and examined for cytotoxic activity against cells infected with JEV. Figure 8 shows the results of CTL assays at various effector to target cell ratios. Thus, mice immunized with RAdEa or RAdEs through IM route showed significant CTL activity. No CTL activity was detectable in mice immunized with RAdEa or RAdEs through oral route. Similarly, unimmunized and Ad5-immunized mice or those immunized with the vaccine showed no CTL activity.

Example – 16

Mice challenge studies: Mice immunized with RAdS were challenged at day 44 post-immunization by intra-cerebral inoculation of a lethal dose (100 LD₅₀) of JEV. These mice were observed for mortality for 3 weeks after the challenge. All mice immunized with 7.5×10^5 or 1×10^8 PFU of RAdEs given IM survived the challenge while none of the unimmunized mice survived. Furthermore, none of the mice immunized IM or orally with 1×10^8 PFU of E1/ E3 Ad5 survived the challenge. About 50-60% protection was seen in mice immunized with 1×10^8 PFU of RAdEs given orally. The level of protection was lower (30%) when mice were immunized orally with lower doses of RAdEs (3×10^5 PFU). The level of protection afforded by RAdEa immunization was very low; about 40% mice survived from those immunized with

7.5×10^5 PFU given IM and only about 20% mice survived from the group immunized with 3×10^6 PFU given orally. In a separate experiment, 15 mice were immunized with 1×10^8 PFU of RAdEs and given 2 booster doses on day 21 and 35. When challenged on day 44 post-immunization with 1000 LD₅₀ of JEV, given intra-cerebral, 100% of the immunized mice survived.

The flavivirus E protein has been the antigen of choice for vaccine development using modern methods of vaccinology such as the DNA vaccination or the use of recombinant virus for antigen delivery (10, 12, 16, 28-31). This has been so because E protein plays an important role in a number of processes, including viral attachment, membrane fusion and entry into the host cell (26). Besides, flavivirus E protein induces virus-neutralizing antibodies and CTLs (14, 14, 15, 22, 23, 34). It has been shown that protection against JEV is mainly antibody dependent, and virus-neutralizing antibodies alone are sufficient to impart protection (19, 32). This was also implied from our previous observation that the formalin-inactivated JEV vaccine, which did not induce CTLs, provided protection to vaccinees against JEV (15). Thus, with a view to develop a recombinant virus-based JEV vaccine, we have constructed RAds synthesizing JEV E protein.

During replication of JEV, the E protein is expressed on the cell surface. Plasmid DNA vectors have been described that synthesize different forms of the E protein, such as the cytoplasmic, membrane-anchored or secretory (2, 6, 7, 15, 20). These different forms of JEV E protein were shown to induce different kind of immune responses. Similarly, recombinants of vaccinia expressing the secretory E protein of Japanese encephalitis or Dengue viruses were found to be highly immunogenic in mice (14, 27, 37). Previously, we had shown that truncated JEV E protein, where the membrane-anchor sequence had been removed by deletion of the C-terminal 102 amino acids, was actively secreted in the cell surroundings (15). We have now constructed RAds that synthesize the membrane-anchored or the secretory E protein.

Oral delivery of RAd has been shown to induce humoral and cellular immune responses to the protein encoded by the transgene, however, these responses have usually been weaker compared to those induced by the IM or intra-peritoneal delivery of RAd (21, 35, 42). In the present study too, oral immunization of mice by RAds resulted in significantly lower anti-JEV antibody titers when compared with the IM route of RAd delivery. Thus, mice immunized IM with 1×10^8 PFU of RAdEs gave

~60-fold higher anti-JEV antibody response than those immunized with the same dose of the virus given orally.

Use of Sodium carbonate buffer to neutralize the pH of the stomach made no perceptible difference to antibody titers when compared with the antibody titers induced by RAdEs given orally without the bicarbonate buffer. In fact, when bicarbonate buffer was used during oral immunization, the booster doses of RAdEs failed to enhance the anti-JEV antibody titers. For RAdEa too, oral delivery resulted in weaker anti-JEV antibody responses compared to the IM delivery of the recombinant. Thus, compared to oral delivery, IM inoculation of 7.5×10^5 PFU of RAdEa (which was half the dose given orally) induced ~100-fold higher anti-JEV antibody titers. The antibody titers were dose dependent. Thus higher doses of RAdEs (1×10^8 PFU) delivered orally induced higher anti-JEV antibody titers. These titers were ~4-fold higher than those induced by the commercial vaccine given IM. Importantly, IM inoculation of RAdEa or RAdEs at both the doses tested (7.5×10^5 and 1×10^8 PFU) resulted in significantly higher antibody responses than those given by the vaccine; 1×10^8 PFU of RAdEs given IM induced ~250-fold higher titer than the vaccine. Similar pattern was reflected in JEV neutralizing antibody titers when oral route of RAds delivery was compared with the IM route although the differences weren't so pronounced. Thus ~20-fold higher JEV neutralizing antibody titers were induced by IM inoculation of 1×10^8 PFU of RAdEs compared to oral delivery of the recombinant. Only statistically insignificant differences were noted in anti-JEV antibody titers induced by 7.5×10^5 PFU of RAdEa and RAdEs given IM. However, there was significant difference in the JEV neutralizing antibody titers generated by the two RAds; a mean JEV neutralizing antibody titer of 10 was obtained when mice were immunized with RAdEa whereas it was 133 when mice were immunized with RAdEs. Higher JEV neutralizing antibody titers were recorded when higher doses of RAdEs were used for immunization. At both the doses tested (7.5×10^5 and 1×10^8 PFU) IM inoculation of RAdEs induced significantly higher JEV neutralizing antibody titers than the commercial vaccine. Thus a dose of 1×10^8 PFU of RAdEs given IM induced 8-fold higher JEV neutralization titer than the vaccine. These differences in JEV neutralizing antibody titers induced by RAdEa and RAdEs by oral and IM inoculation were reflected in the level of protection afforded by these recombinants to the immunized mice against lethal JEV challenge. Thus both doses of RAdEs inducing JEV

neutralizing antibody titers higher than the vaccine gave 100% protection. Immunization with RAdEs or RAdEa given orally gave only low levels of protection. Challenge experiments indicated that mice immunized IM with the adenovirus synthesizing the membrane-anchored form of JEV E protein did not develop protective immunity whereas those immunized with recombinant synthesizing the secretory form of JEV E protein developed robust anti-JEV protective immunity resulting in 100% protection. These results show that RAd-based JEV immunizations are superior to naked DNA immunizations, which imparted only about 50-60% protection in a mouse challenge model (15). It is interesting that level of protection was similar (50-60%) when mice were immunized with plasmid DNA synthesizing Ea or Es proteins (15) whereas in the present work Es induced significantly superior protective immune response than the Ea protein. This may be related to a more efficient delivery of JEV transgene using RAd than the direct injection of naked plasmid DNA for immunization. Our finding is, however, consistent with reports from others where truncated form of JEV or Dengue E protein (leading to its secretion) was found to be more immunogenic than the membrane-anchored form of the E protein (14, 37). Poor anti-JEV antibody induction by oral immunization with RAdEs was also reflected in poor cytokine secretion by splenocytes in presence of JEV. While very little IFN- γ was secreted by splenocytes from mice immunized orally with RAdEs or RAdEa, significant amounts of IFN- γ were secreted by splenocytes obtained from mice immunized IM with RAdEa or RAdEs. Splenocytes from IM immunized mice also synthesized moderate amounts of IL-5 that was not detectable in cultures of splenocytes obtained from mice immunized orally with RAdEs. Mice immunized IM with both RAdEa and RAdEs had significant CTL activity, which was undetectable in mice immunized orally with RAdEs or IM with the vaccine. Oral immunization with RAdEs at lower dose resulted in IgG1 dominated immune responses; ratio of IgG1/IgG2a endpoint titers was 6.5. This is consistent with studies on oral immunization of mice with RAd synthesizing rabies glycoprotein where abundance of anti rabies IgG1 was recorded (46). The IM inoculation of RAdEa and RAdEs also resulted in preponderance of IgG1 kind of antibodies. No data could be found in literature on antibody isotypes when adenovirus recombinants are delivered IM. Our results indicating the preponderance of IgG1 type antibodies, secretion of IFN- γ and IL-5 by splenocytes and induction of CTLs suggest that IM inoculation of mice with RAdEs

synthesizing JEV E protein activates both the humoral and the cellular arms of the immune system, and immune responses of both Th1 and Th2 type are induced.

The results presented in this invention show that RAd synthesizing the secretory form of JEV E protein imparted robust immunity in mice against lethal dose of JEV given intra-cerebral. This makes RAdEs a potential candidate vaccine against JEV. Further, safety profile of the vaccine of the instant application was studied. The vaccine is found to be safe for administration. None of the immunized mice showed any obvious complications.

Application Project

<120> Title : A recombinant vaccine against Japanese encephalitis virus (JEV) infection and a method thereof

<130> AppFileReference : IP 1340

<140> CurrentAppNumber : 1516/Del/203

<141> CurrentFilingDate : 2003-12-04

Sequence

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

```

cgtaactata acggtcctaa ggtagcga aa gctcagatct ggatctcccg atcccctatg    60
gtcactctc agtacaatct gctctgatgc cgcatagtta agccagtatc tgctccctgc    120
ttgtgtgtg gaggtcgtg agtagtcgc gagcaaaatt taagctacaa caaggcaagg    180
cttgaccgac aattgcatga agaactgct tagggtagg cgtttgcgc tgcttcgca    240
tgtacgggcc agatatacgc gttgacattg attattgact agtattaat agtaataat    300
tacggggta ttagttcata gccatataat ggagttccgc gttacataac ttacggtaaa    360
tggcccgctt ggctgaccgc ccaacgaccc ccgccattg acgtcaataa tgacgtatgt    420
tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggact atttacgga    480
aactgccac ttggcagtag atcaagtga tcatatgcca agtacgccc ctattgacgt    540
caatgacggt aatggcccgc cctggcatta tgcccagtag atgacctat gggactttcc    600
tactggcag tacatctacg tattagtcac cgctattacc atggtgatgc ggtttggca    660
gtacatcaat gggcgtggat agcgtttga ctacgggga ttccaagtc tcccccacat    720
tgacgtcaat gggagtttgt ttggcacca aatcaacgg gactttcaa aatgtcgtaa    780
caactccgc ccattgacgc aaatgggcgg taggcgtgta cgggtggagg tctatataag    840
cagagctctc tggtaacta gagaaccac tgcttactgg ctatcgaaa ttaatacagc    900
tcaactatag gagaccaag ctggctagcg tttaaacggg cctctagac tcgagcggcc    960
gccactgtgc tggatgatcc gagtcggtta ccatgtggct cgcaagcttg gcagttgtca    1020
tagcttgcgc agggagccatg aagttgtcga atttccaggg gaagcttttg atgaccatca    1080
acaacacgga cattgcagac gttatcgtga tttccacctc aaaaggagag aacagatgct    1140
gggtccgggc aatcgacgtc ggttacatgt gtgaggacac catcacgtac gaatgtccta    1200
agcttactgc gggcaatgat ccagaggacg tggattgctg gtgtgacaac caagaagtct    1260
acgtccaata tggacggtag acgcggacca ggcattccaa gcgaagcagg agatccgtgt    1320
cgggtccagc acatggggag agttcactag tgaataaaaa agaggcttgg ctggattcaa    1380
cgaaagccac acgatatctc acgaaaactg agaactggat cataaggaat cctggctatg    1440
ctttcttggc ggcggtactt ggctggatgc ttggcagtaa caacggtcaa cgcgtggtat    1500
ttaccatcct cctgctgttg gtcgtccgg cttacagttt taattgtctg ggaatgggca    1560
atcgcgactt catagaagga gccagtggag ccacttgggt ggacttgggt ctagaaggag    1620
atagctgttt gacaatcatg gcaaacgata aaccaacatt ggatgtccgc atgattaaca    1680
tcgaagctag ccaacttgcg gaggtcagaa gttattgcta tcatgcctca gtcactgaca    1740
tctcgacggt ggctcgggtc cccatgactg gagaagctca caacgagaag cgagctgata    1800
gtagctatgt gtgcaaaaca ggcttactg atcgtgggtg gggcaacgga tgtggacttt    1860
tcgggaaggg aagcattgac acatgtgcaa aattctcctg caccagcaaa gcgattggga    1920
gaacaatcca gccagaaaac atcaaatacg aagtggcat tttgtgcat ggaaccacca    1980
cttcggaaaa ccatgggaat tactcagcgc aagtggggc gtcccaggcg gcaaagtta    2040
ccgtaacacc caatgctcct tcgataaccc tcaaacttgg tgactacgga gaagtacac    2100
tggactgtga gccaaaggag ggactgaaca ctgaagcgtt ttacgtcatg accgtggggt    2160
caaagtcatt tctgggtcat agggaatggt tcatgacct cgctctcccc tggacgtccc    2220
cttcgagcac agcgtggaga aacagagaac tctcatgga atttgaagag gcgcacgcca    2280

```

caaaacagtc cgttgttgc cttggttcac aggaaggagg cctccatcag gcgttggcag 2340
 gagccatcgt ggtggagtac tcaagctcag tgaagttaac atcaggccac ctgaaatgta 2400
 ggctgaaaat ggacaaacta gctctgaaag gcacaaccta tggcatgtgt acagaaaaat 2460
 tctcgttcgc gaaaaatccg gcggacactg gtcacggaac agttgtcatt gaactctcct 2520
 actctgggag tgatggcccc tgcaaaatc cgattgtctc cgtcgcgagc ctcaatgaca 2580
 tgactcctgt tggcgggctg gtgacagtga acccctttgt cgcggcttcc agtgccaact 2640
 caaagggtct ggtcagatg gaacccccct tcggagactc ctatatcgtg gttggaaggg 2700
 gagacaagca gatcaaccac cattggcaca aataataaag gatctgtgtg ttgccccctc 2760
 cccgtgcctt ccttgacctt ggaagggtgc actccactg tcctttccta ataaaatgag 2820
 gaaattgcat cgcattgtct gagtaggtgt cattctattc tgggggggtg ggtggggcag 2880
 gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggtct 2940
 atggcttctg aggcggaaag aaccagcaga tctgcagatc tgaattcatc tatgtcgggt 3000
 gcggagaaag aggtaatgaa atggcatcga ctggaagatc tggcggtgtg taagggtggg 3060
 aaagaatata taagggtggg gtcttatgta gttttgtatc tgttttgag cagccgccgc 3120
 cgcatgagc accaactcgt ttgatggaag cattgtgagc tcatattga caacgcgat 3180
 gccccatgg gccgggggtg gtcagaatgt gatgggtccc agcattgatg gtcgccccgt 3240
 cctgccccga aactctacta ccttgacctc cgagaccgtg tctggaacgc cgttgagagc 3300
 tgacgctcc gcccgccgtt cagccgtgc agccaccgcc cgcgggattg tgactgactt 3360
 tgctttctg agcccgctt caagcagtgc agcttcccgt tcatccgcc gcgatgaca 3420
 gttgacggct ttttggcac aattggattc ttgaccggg gaactaatg tegtttctca 3480
 gcagctgtg gatctgcgc agcagggttc tgcctgaag gcttctccc ctccaatgc 3540
 ggtttaaaac ataaataaaa aaccagactc tgtttggatt tggatcaagc aagtgtctg 3600
 ctgtctttat ttgggggtt tgcggcgcg gtagggccgg gaccagcggt ctcggtcgtt 3660
 gaggtcctg tgtatttttt ccaggacgtg gtaaaagtga ctctggatgt tcagatacat 3720
 gggcataagc cgtctctg ggtggaggta gcaccactgc agagcttcat gctcgggggt 3780
 ggtgtgtag atgatccagt cgtagcagga gcgtggcg tgggtcctaa aaatgtcttt 3840
 cagtagcaag ctgattgcca ggggcaggcc ctgtgtgtaa gtgtttacaa agcggttaag 3900
 ctgggatggg tgcatactg gggatatgag atgcattctg gactgtattt ttaggttggc 3960
 tatgttccca gccatatccc tccggggatt catgttgtgc agaaccacca gcacagtgt 4020
 tccggtgcac ttgggaaatt tgtcatgtag cttagaagga aatgcgtgga agaacttga 4080
 gacgcccctg tgacctcaa gattttccat gcattcgtcc ataagtatg caatggggcc 4140
 acggggcgcg gcctggcgga agatatttct gggatcacta acgtcatagt tgtgttccag 4200
 gatgagatcg tcataggcca tttttacaa gcgcggggcg aggggtccag actgcgggtat 4260
 aatggttcca tccggcccag gggcgtagtt accctcacag atttgattt cccacgcttt 4320
 gagttcagat ggggggatca tgtctacctg cggggcgatg aagaaaacgg tttccgggt 4380
 aggggagatc agctgggaag aaagcagggt cctgagcagc tgcgacttac cgcagccgt 4440
 gggcccgtaa atcacaccta ttaccggctg caactggtag ttaagagagc tgcagctgcc 4500
 gtcatccctg agcagggggg ccacttcgtt aagcatgtcc ctgactcgca tgttttcct 4560
 gaccaaattc gccagaaggc gctcgccgcc cagcagatgc agttcttga aggaagcaaa 4620
 gtttttaac ggttttagac cgtccgccgt aggcagctt ttgagcgtt gaccaagcag 4680
 ttccaggcgg tcccacagct cggtcactg ctctacggca tctgatcca gcatactcc 4740
 tegtttcgc ggttggggcg gctttcgtg tacggcagta gtcggtgctc gtccagacgg 4800
 gccagggtca tgttttcca cgggcgcagg gtctctgca gcgtagtctg ggtcacgggt 4860
 aagggtgcg ctccggcgct cgcgtggcc aggggtgcgt tgaggctggt cctgctggtg 4920
 ctgaagcgt gccggtctt gccctgcgc tcggccaggt agcatttgac catggtgtca 4980
 tagtcagcc cctccgggc gtggccctg gcgcgcagct tgcccttga ggaggcgccg 5040
 cagaggggc agtgagact tttgaggcg tagagcttg gcgcgagaaa taccgattcc 5100
 ggggagtagg catccgcgc gcaggcccc cagacggtct cgcattccac gagccagggt 5160
 agctctggcc gttcgggtc aaaaaccagg ttcccccat gcttttgat gcgtttctta 5220
 cctcgggtt ccatgagccg gttccacgc tcggtgacga aaaggctgc cgtgtccccg 5280

tatacagact tgagaggcct gtcctcgagc ggtgttccgc ggtcctcctc gtatagaaac 5340
 tcggaccact ctgagacaaa ggctcgcgtc caggccagca cgaaggaggc taagtgggag 5400
 gggtagcggg cgttgtccac taggggggtcc actcgtcca ggggtggaag acacatgtcg 5460
 ccctcttcgg catcaaggaa ggtgattggt ttgtagggtg agggccacgtg accgggtgtt 5520
 cctgaagggg ggctataaaa ggggggtggg gcgcgtctgt cctcactctc ttccgcatcg 5580
 ctgtctcgga gggccagctg ttgggggtgag tactccctct gaaaagcggg catgacttct 5640
 gcgctaagat tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcggtg 5700
 atgcctttga ggggtggcgc atccatctgg tcagaaaaga caatctttt gttgtcaagc 5760
 ttggtggcaa acgaccctga gaggcggtg gacagcaact tggcgatgga gcgcagggtt 5820
 tggttttgt cgcgatcggc gcgcctctg gcccgatgt ttagctgcac gtattcgcgc 5880
 gcaacgcacc gccattcggg aaagacgggt gtgcgctcgt cgggcaccag gtgcacgcgc 5940
 caaccgggt tgtgcagggt gacaaggta acgctgggtg ctacctctcc gcgtaggcgc 6000
 tcgttggtcc agcagaggcg gccgccctg gcgagcaga atggcggtg ggggtctagc 6060
 tgcgtctcgt cgggggggtc tgcgtccacg gtaaaagacc cgggcagcag gcgcgcgtcg 6120
 aagtagtcta tctgcatcc ttgcaagtct agcgcctgct gccatgcgcg ggcggcaagc 6180
 gcgcgctcgt atgggttagg tgggggaccc catggcatgg ggtgggtgag cgcggaggcg 6240
 tacatggcg aaatgtccta aacgtagagg ggctctctga gtattcaag atatgtaggg 6300
 tagcatctc caccgcggat gctggcgcg acgtaatcgt atagttcgt cgaggaggcg 6360
 aggaggtcgg gaccgaggt gctacggcg gcctgctctg ctgggaagac tatctgcctg 6420
 aagatggcat gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct 6480
 gtgagacct cgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc 6540
 tcggcggtga cctgcacgtc tagggcgag tagtccaggg ttctctgat gatgcatac 6600
 ttatctgtc cctttttt ccacagctcg cggttgagga caaactctc gcggtcttc 6660
 cagtactct ggatcggaac ccgctcgcc tcgaacggg aagagcctag catgtagaac 6720
 tggtagcgg cctggtaggt gcagcatccc tttctacgg gtagcgcta tgctgcgcg 6780
 gccttcgga gcgaggtgtg ggtgagcga aaggtgtccc tgaccatgac ttgaggtac 6840
 tggtagtga agtcagctc gtcgcatcg cctgctccc agagcaaaa gtccgtgcgc 6900
 ttttggaa gcggattgg caggcggaag gtgacatcgt tgaagagtat ctttcccgcg 6960
 cgaggcataa agttgcgtg gatgcggaag ggtcccggca cctcggaacg gttgtaatt 7020
 acctgggagg cgagcacgat ctgctcaag ccgttgatgt tgtggccac aatgtaagt 7080
 tccaagaagc gcgggatgcc ctgatggaa ggcaatttt taagtcttc gtaggtgagc 7140
 tcttcagggg agctgagccc gtgctctgaa agggccagc ctgcaagatg aggggtggaa 7200
 gcgacgaat agtccacag gtacggggcc attagcatt gcagggtgtc gcgaagggtc 7260
 ctaaactggc gacctatggc cttttttt ggggtgatgc agtagaaggt aagcgggtct 7320
 tgttccagc ggtcccatcc aaggttcgc gctagggtc gcgcggcag cactagaggc 7380
 tcatctccg cgaacttcat gaccagcatg aagggcacga gctgctccc aaaggcccc 7440
 atccaagtat aggtctctac atcgtagggtg acaaagagac gtcgggtgcg aggatgcgag 7500
 ccgatcggga agaactggat ctccgccac caattggagg agtggctatt gatgtggtga 7560
 aagtagaagt cctgcgacg ggccgaacac tctgctggc tttgtaaaa acgtgcgag 7620
 tactggcagc ggtgcacggg ctgtacatcc tgcacagggt tgacctgac accgcgaca 7680
 aggaagcaga gtgggaatt gagcccccg cctggcggtt ttggctggtg gtcttctact 7740
 tcggctgctt gtccttgacc gtcgggtgc tcgaggggag ttacgggtgga tcggaccacc 7800
 acgcgcgcg agcccaagt ccagatgtcc gcgcgcggcg gtcggagctt gatgacaaca 7860
 tcgcgcagat gggagctgtc catggctgg agtcccgcg gcgtcaggtc aggcgggagc 7920
 tcttcaggt ttacctcga tagacgggtc agggcgcggg ctatgccag gtgatacta 7980
 atttccagg gctgggtggt ggcgcgctc atggcttga agaggccga tccccgcgc 8040
 gcgactagg taccgcgcg cggcggtggt gccgcggggg tctcttga tgatcatct 8100
 aaaagcggg acgcggcgga gcccccggag gtggggggg ctccggacc gccgggagag 8160
 ggggcagggg cagctcggcg ccgcgcggg gcaggagctg gtgctgcgc gtaggttgc 8220
 tggcgaacg cagcacgcgg cggttgatct cctgaatctg gcgcctctgc gtgaagacga 8280

cgggccccgt gagcttgaac ctgaaagaga gttcgacaga atcaatttcg gtgtcgttga 8340
 cggcggcctg gcgcaaaatc tcttcacgt ctctgagtt gtcttagatg gcgatctcgg 8400
 ccatgaactg ctgatctct tctctctgga gatctccgcg tccggctcgc tccacgggtg 8460
 cggcgagggtc gttggaatg cgggccatga gctgcgagaa ggctgtgagg cctccctcgt 8520
 tcagacgcg gctgtagacc acgccccctt cggcatcgcg ggcgcgcatg accacctgcg 8580
 cgagattgag ctccacgtgc cggcggaaga cggcgtagtt tcgcaggcgc tgaagagggt 8640
 agttgagggt ggtggcgggtg tgttctgcca cgaagaagta cataaccag cgtcgcaacg 8700
 tggattcgtt gatattcccc aaggcctcaa ggctctccat ggctctctag aagtcacgg 8760
 cgaagttaa aaactgggag ttgcgcgccg acacgggtta ctctctctc agaagacgga 8820
 tgagctcggc gacagtgtcg gcacctcgc gctcaaaggc tacaggggccc tcttcttct 8880
 cttaactc ctctccata agggcctccc ctcttcttc ttctggcggc ggtgggggag 8940
 gggggacacg gggcgacga cggcgaccg ggaggcggtc gacaaagcg tcgatcatct 9000
 ccccgcgcg acggcgcatg gtctcggtga cggcgcgcc gtctcgcgg gggcgagtt 9060
 ggaagacgcc gcccgatg tcccggttat ggggtggcgg gggcgctgcca tgcggcaggg 9120
 atacggcgt aacgatgcat ctcaacaatt gttgtgtagg tactccgccg ccgagggacc 9180
 tgagcgagtc cgcacgacc ggatcggaac acctctcag aaaggcgtct aaccagtcac 9240
 agtcgaagg taggctgagc accgtggcgg gcgcgacggc gggcggtcg ggggtgttc 9300
 tggcgagggt gctgctgatg atgtaattaa agtaggcgt cttagacgg cggatggtcg 9360
 acagaagcac catgtcttg ggtccggcct gctgaatcg caggcggtcg gccatgcccc 9420
 aggtctcgt ttgacatcg cgcaggcttt ttagtagtc ttgcatgac ctctctaccg 9480
 gcaattctc ttctcttc tcttctctg catctctgc atctatcgt cggcgggcgg 9540
 cggagtttgg ccgtagggtg cggctcttc ctccatgcg tgtgacccg aagccccca 9600
 tcggctgaag caggcgtagg tcggcgaca cgcgctcggc taatatggcc tctgcacct 9660
~~gcgtaggggt agactggag tcatccatgt ccaaaagcg gtagtagcg ccggtgtga~~ 9720
 tgggtgaagt gcagttggcc ataacggacc agttaacggt ctggtagacc ggtcgaga 9780
 gctcggtgta cctgagacgc gagtgaagccc tcgagtcaa tactagtcg ttgcaagtc 9840
 gcaccaggta ctggtatccc accaaaaagt gggcgggcgg ctggcggtag aggggcccagc 9900
 gtaggggtggc cggggctccg gggcgagat ctccaacat aaggcgatga tatccgtaga 9960
 tgtacctga catccagggt atgcggcgg cgggtggtga ggcgcgcgga aagtcgcca 10020
 cgcggttcca gatgttcgc agcggaaaa agtctccat ggtcgggacg ctctggccgg 10080
 tcaggcgcg gcaatcgtg acgctctagc gtgaaaagg agagcctga agcgggcact 10140
 ctccgtggt ctggtggata aattcgcaag ggtatcatgg cggacgaccg gggttcgagc 10200
 cccgtatccg gccgtccgc gtgatccat cggttaccg ccgctgtcg aaccagggtg 10260
 tgcgacgta gacaacgggg gagtgtctt ttggcttc ttccaggcg ggcggtgct 10320
 gcgctagct ttttggccac tggccgcgc cagcgtgaag ggttaggctg gaaagcgaaa 10380
 gcattaagt gtcgctccc ttagccgga gggttatctt ccaagggtg agtcgaggga 10440
 cccccgttc gagtctcga ccggccggac tgcggcgaa gggggttgc ctccccgta 10500
 tgcaagacc cgcttgcaa ttctccgga aacagggacg agccccctt ttgctttcc 10560
 cagatgcat cgggtgtcg cgagatgct cccctctc agcagcgga agagcaagag 10620
 cagcggcaga catgcaggc accctcccc ctctctaccg cgtcaggagg ggcgacatcc 10680
 gcggttgac cggcagcaga tgggtattac gaacccccgc ggcgccggc ccggcactac 10740
 ctggacttgg aggagggcg gggcctggcg cggctaggag cgccctctc tgagcgac 10800
 ccaagggtgc agctgaagc gtatcgctg gaggcgtacg tgcccgcgga gaacctgtt 10860
 cgcgaccgc agggagagga gcccgaggag atcggggac gaaagttcca cgcagggcgc 10920
 gagtcggc atggcctgaa tcgcgagcg ttgctgcgc aggaggactt tgagcccgac 10980
 gcgcgaacc ggattagtcc cgcgcgcga cagtgggcg ccgcgacct ggtaaccgca 11040
 tacgagcaga cggtaacca ggagattaac ttcaaaaaa gctttaaca ccagtgct 11100
 acgcttggc cgcgcgagga ggtggctata ggactgatg atctgtggga cttgtgaagc 11160
 gcgctggagc aaaacccaaa tagcaagccg ctcatggcg agctgttct tatagtgcag 11220
 cacagcagg acaacgagc attcaggat cgcgtgctaa acatagtaga gcccaggggc 11280

1340-IP.WorkFile

cgctggctgc tcgattgat aaacatcctg cagagcatag tgggtgcagga gcgcagcttg 11340
 agcctggctg acaagggtggc cgccatcaac tattccatgc ttagcctggg caagttttac 11400
 gcccgaaga tataccatac cccttacgtt cccatagaca aggaggtaaa gatcgagggg 11460
 ttctacatgc gcatggcgct gaagggtgctt accttgagcg acgacctggg cgttatcgc 11520
 aacgagcgca tccacaaggc cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag 11580
 ctgatgcaca gcctgcaaag ggccctggct ggcacgggca gcggcgatag agaggccgag 11640
 tcctactttg acgcggggcg tgacctgcgc tgggccccaa gccgacgcgc cctggaggca 11700
 gctggggcgc gacctgggct ggcgggtggca cccgcgcgcg ctggcaactg cggcggcgctg 11760
 gagggaatag acgaggacga tgagtacgag ccaggaggcg gcgagtacta agcgggtgatg 11820
 tttctgatca gatgatgcaa gacgcaacgg acccgggcgt gcggggcgcg ctgcagagcc 11880
 agccgtccgg ccttaactcc acggacgact ggcgccaggt catggaccgc atcatgtcgc 11940
 tgactgcgcg caatcctgac gcgttcggcg agcagccgca ggccaaccgg ctctccgcaa 12000
 ttctggaagc ggttggtccc gcgcgcgcaa accccacgca cgagaagggt ctggcgatcg 12060
 taaacgcgct ggccgaaaac agggccatcc ggcccagca ggccggcctg gtctacgacg 12120
 cgctgcttca gcgcgtggct cgttacaaca gcggcaactg gcagaccaac ctggaccggc 12180
 tgggtggggga tgtgcgcgag gccgtggcg agcgtgagcg gcgcgagcag cagggaacc 12240
 tgggtcccat ggttgacta aacgccttcc tgagtacaca gcccgaac gtgccgggg 12300
 gacaggagga ctacaccaac ttgtgagcg cactgcggct aatggtgact gagacaccgc 12360
 aaagtgggt gtaccagtct gggccagact atttttcca gaccagtaga caaggcctgc 12420
 agaccgtaaa cctgagccag gctttcaaaa acttgaggcg gctgtggggg gtgcgggctc 12480
 ccacaggcga ccgcgcgacc gtgtctagct tgctgacgcc caactcgcgc ctgtgtctgc 12540
 tgctaatagc gcccttcag gacagtggca gcgtgtccc ggacacatac ctaggctact 12600
 tgctgacct gtaccgcgag gccataggtc aggcgcagct ggacgagcat actttccagg 12660
 agattacaag tgtcagccgc gcctggggc agggagacac ggacagcctg gaggaaccc 12720
 taaactacct gctgaccaac cgcggcgaga agatccctc gtgtacagt ttaacagcg 12780
 agggaggcgc catittgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg 12840
 gggtaaccgc cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcagtatg 12900
 cctcaaacgg gccgtttatc aaccgcctaa tggactact gcatcgcgcg gccgcccgtg 12960
 accccagta ttccaat gccatctga accgcactg gctaccgcc cctggtttct 13020
 acaccggggg attcgaggtg cccgagggtg acgatggatt ccttggggac gacatagcg 13080
 agcgcgtgtt ttccccgaa ccgagaccc tgctagagtt gcaacagcg gagcaggcag 13140
 aggcggcgct gcgaaggaa agcttcgcga ggccaagcag ctgtccgat ctaggcgctg 13200
 cggccccgcg gtcagatgct agtagccat ttcaagctt gatagggtct cttaccagca 13260
 ctgcaccac ccgccgcgc ctgctggcg agggaggta cctaaacaac tcgctgctgc 13320
 agccgcagcg cgaaaaaac ctgcctccgg catttccaa caacgggata gagagcctag 13380
 tggacaagat gtagtagtg aagacgtac gcaggagca caggggactg ccaggccgcg 13440
 gcccgccac ccgtgtaaa aggcacgacc gtcagcgggg tctggtgtgg gaggacgatg 13500
 actcggcaga cgacagcag gtcttgatt tgggaggag tggcaaccg ttgcgcacc 13560
 ttcccccag gctggggaga atgttttaa aaaaaaaaaa gcatgatgca aaataaaaaa 13620
 ctaccaagg ccatggcacc gacgttggt ttctgtat tcccctagt atgcggcgcg 13680
 cggcgatga tgaggaggt cctctccct cctacgagag tgtgtgagc gcggcgccag 13740
 tggcgccggc gctgggttct ccttcgatg cctccctgga cccgctgtt gtgcctccgc 13800
 ggtacctcg gcctaccggg gggagaaaca gcatccgta ctctgagtg gcaccctat 13860
 tcgacaccac ccgtgtgtac ctgggtgaca acaagtcaac ggatgtggca tccctgaat 13920
 accagaacga ccacagcaac ttctgacca cggtcattca aaacaatgac tacagcccg 13980
 gggaggcaag cacacagacc atcaatctt acgaccggtc gcactggggc ggcgacctga 14040
 aaaccatct gcatacaac atgccaatg tgaacgagtt catgtttacc aataagtta 14100
 aggcgcgggt gatggtgtcg cgcttgcta ctaaggacaa tcagggtggag ctgaaatag 14160
 agtgggtgga gttcacgctg cccgagggca actactcca gaccatgacc atagacctta 14220
 tgaacaacgc gatcgtggag cactactga aagtgggcag acagaacggg gttctggaaa 14280

gcgacatcgg ggtaaagttt gacaccgcga acttcagact ggggtttgac cccgtcactg 14340
 gtcttgcac gcctggggta tatacaaacg aagccttcca tccagacatc attttgcgc 14400
 caggatgcgg ggtggacttc acccacagcc gcctgagcaa ctgttgggc atccgcaagc 14460
 ggcaaccctt ccaggagggc tttaggatca cctacgatga tctggagggt ggtaacattc 14520
 ccgactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc gaacagggcg 14580
 ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc ggaagagaac tccaacgcgg 14640
 cagccgcggc aatgcagccg gtggaggaca tgaacgatca tgccattcgc ggcgacacct 14700
 ttgccacagc ggctgaggag aagcgcgctg aggcggaagc agcggccgaa gctgccccc 14760
 ccgtcgcga acccgaggtc gagaagcctc agaagaaacc ggtgatcaa cccctgacag 14820
 aggacagcaa gaaacgcagt tacaacctaa taagcaatga cagcaccttc acccgtacc 14880
 gcagctggta cttgcatac aactacggcg accctcagac cggaaaccgc tcatggacc 14940
 tgctttgcac tctgacga acctgcggct cggagcaggt ctactgctg ttgccagaca 15000
 tgatgcaaga ccccgtagc tccgctcca cgcgccagat cagcaacttt cgggtgggtg 15060
 gcgcccagct gttcccgtg cactccaaga gcttctcaa cgaccaggcc gtctactccc 15120
 aactcatccg ccagtttacc tctctgccc acgtgttcaa tcgtttccc gagaaccaga 15180
 ttttggcgcg cccgccagcc ccaccatca ccaccgtcag tgaacacgtt cctgctctca 15240
 cagatcacgg gacgctaccg ctgcgcaaca gcacggagg agtccagcga gtgaccatta 15300
 ctgacgccag acgcgcacc tgcccctacg ttacaaggc cctgggcata gtctcgcgc 15360
 gcgtctatc gagccgact tttgagcaa gcattgcat ccttatctg cccagcaata 15420
 acacaggctg gggcctgcgc ttccaagca agatgtttg cggggccaag aagcgtccg 15480
 accaacaccc agtgcgctg cgccggcact accgcgcgc cggggcgcg cacaacgcg 15540
 gccgactgg gcgcaccacc gtcgatgacg ccatcgacgc ggtggtggag gaggcgcgca 15600
 actacagcc cagccgccca ccagtgtcca cagtggacgc ggcattcag accgtggtg 15660
 gcggagcccg gcgctatgt aaaaagaaga gacggcgag gcgctagca cgtgcacc 15720
 gccgcgacc cggcctgac gcccaacgc cgcggcgcc cctgctaac cgcgcagtc 15780
 gcaocggcg acggcgccg atcgggcg ctcgaaggct ggcgcgggt attgtcactg 15840
 tgccccag gtccaggcga cgagcgccg ccgagcagc cgcggccatt agtgcctatga 15900
 ctgagggtc caggggcaac gtgtattggg tgcgcgact ggttagcgcc ctgcgctgc 15960
 ccgtgcgac cgcggcgcc cgaactaga ttgcaagaaa aaactacta gactcgtact 16020
 gttgtatga tccagcgcg gcggcgcgca acgaagctat gtccaagcgc aaatcaaaag 16080
 aagagatgt ccaggtcac gcgcgggaga tctatggccc ccgaagaag gaagagcagg 16140
 attacaagcc ccgaagcta aagcgggtca aaaagaaaaa gaaagatgat gatgatgaac 16200
 ttgacgacga ggtggaactg ctgcacgcta ccgcggccag gcgacgggta cagtggaaag 16260
 gtcgacgctg aaacgtgtt ttgcgacccg gcaccaccgt agtctttacg cccgtgagc 16320
 gtcaccccg cactacaag gcgtgtatg atgaggtga cggcgacgag gactgcttg 16380
 agcaggccaa cgagcgctc ggggagttg cctacggaaa gcggcataag gacatgctg 16440
 cgttgcgct ggacgaggc aaccacac ctacgctaaa gccgtaaca ctgcagcagg 16500
 tgctcccg cgtgcaccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact 16560
 tggacccac cgtgcagct atggtacca agcgcagcg actggaagat gtcttgaaa 16620
 aaatgacct ggaacctgg ctggagccc aggtccgct gcggccaatc aagcaggtg 16680
 cgccgggact gggcgtgcag accgtggacg ttcagatacc cactaccagt agcacagta 16740
 ttgccaccg cacagaggc atggagacac aaacgtccc ggttgcctca gcgtggcg 16800
 atgcccggt gcaggcggtc gtcgcgccg cgtccaagac ctctacggag gtgcaaacgg 16860
 accgtggat gtttcgctt tcagccccc ggcggcccg ccgttcgagg aagtacggcg 16920
 ccgacagcg gctactccc gaatatccc tacatcctc cattgcgct accccggct 16980
 atcgtggcta cactaccg cccagaagac gagcaactac ccgacggcga accaccctg 17040
 gaacccgcg ccgctgcgc cgtgcgacg ccgtgctgg cccgatttcc gtgcgagg 17100
 tggctcgca agggagcagg accctggtg tgccaacagc gcgctaccac ccagcatcg 17160
 tttaaagcc ggtcttctg gtcttcgag atatggccct cacctgccg ctccgtttcc 17220
 cgggtccggg attccgagga agaatgacc gtagggggg catggccgc cagcgctga 17280

1340-IP.WorkFile

cggcgggcat gcgtcgtgcg caccaccggc ggccggcgcgc gtcgcaccgt cgcgtcgcgc 17340
 gcggtatcct gcccctcctt attccactga tcgccgcggc gattggcgcg gtgcccggaa 17400
 ttgcatccgt ggcccttgag gcgcagagac actgattaaa aacaagtgc atgtggaaaa 17460
 atcaaaataa aaagtctgga ctccacgct cgcttggtcc tgtaactatt ttgtagaatg 17520
 gaagacatca actttgcgtc tctggccccg cgacacggct cgcgccgtt catgggaac 17580
 tggcaagata tcggcaccag caatatgagc ggtggcgccct tcagctgggg ctcgctgtgg 17640
 agcggcatta aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc 17700
 agcacaggcc agatgctgag ggataagttg aaagagcaaa atttcaaca aaaggtggtg 17760
 gatggcctgg cctctggcat tagcgggggtg gtggacctgg ccaaccaggc agtgcaaaat 17820
 aagattaaca gtaagcttga tccccgcct cccgtagagg agcctccacc ggccgtggag 17880
 acagtgtctc cagagggggcg tggcgaaaag cgtccgcgcc ccgacaggga agaaactctg 17940
 gtgacgcaaa tagacgagcc tccctcgtac gaggaggcac taaagcaagg cctgccacc 18000
 accgtcccca tcgcgccat ggctaccgga gtgctggggc agcacacacc cgtaacgctg 18060
 gacctgccit cccccgccga caccagcag aaacctgtgc tgcaggccc gaccgccgtt 18120
 gttgtaacc gtcctagccg cgcgtccctg cgcgcgccg ccagcggcc gcgacgtt 18180
 cgccccgtag ccagtggcaa ctggcaaaag aactgaaca gcatcgtggg tctgggggtg 18240
 caatccctga agcgcgcgac atgcttctga tagctaactg gtcgtatgtg tgtcatgtat 18300
 gcgtccatgt cgcgccaga ggagctgctg agccgcgcg cgcgcgtt ccaagatggc 18360
 tacccttcg atgatccgc agtggctta catgcacac tcggggcagg acgcctcgga 18420
 gtacctgagc cccgggctgg tgcagtttgc ccgcgccacc gagacgtact tcagcctgaa 18480
 taacaagttt agaaaccca cgggtggcgc tacgcacgac gtgaccacag accggtcca 18540
 gcgtttgacg ctgcggttca tccctgtgga ccgtgaggat actgcgtact cgtacaaggc 18600
 gcggttcacc ctagctgtgg gtgataaccg tgtctgggac atggcttcca cgtacttga 18660
 catccggcg gtgctggaca gggggcctac ttttaagccc tactctggca ctgcctaca 18720
 cgccctggct ccaagggtg ccccaaatcc ttgcaatgg gatgaagctg ctactgctt 18780
 tgaataaac ctagaagaag aggcagatga caacgaagc gaagtagagc agcaagctga 18840
 gcagcaaaa actcacgtat ttgggcaggc gcctattct ggtataaata ttacaagga 18900
 ggggtattca ataggtgtcg aaggtcaaac acctaaatat gccgataaaa cattcaacc 18960
 tgaacctcaa ataggagaat ctgagtgga cgaacagaa attaatcatg cagctgggag 19020
 agtcctaaaa aagactaccc caatgaaacc atgtacggg tcatatgcaa aaccacaaa 19080
 tgaatatgga gggcaaggca ttctgtaaa gcaacaaat ggaaagctag aaagtcaagt 19140
 ggaaatgcaa ttttctcaa ctactaggc agccgcaggc aatggtgata acttgactcc 19200
 taaagtggta ttgtacagt aagatgtaga tatagaacc ccagacactc atatttcta 19260
 catgcccact attaaagga gtaactcacg agaactaat ggccaacaa ctatgcccc 19320
 caggcctaata tacattgctt ttagggacaa tttattggt ctaatgtatt acaacgac 19380
 gggtaatatg ggtgttctgg cgggccaagc atcgagttg aatgctgttg tagatttga 19440
 agacagaaac acagagcttt cataccagct ttgcttgat tccattgggt atagaaccag 19500
 gtacttttct atgtggaatc aggtgttga cagctatgat ccagatgta gaattattga 19560
 aatcatgga actgaagatg aacttccaa ttactgctt cactgggag gtgtgattaa 19620
 tacagagact ctaccaagg taaaacctaa aacaggctag gaaatggat gggaaaaaga 19680
 tgctacagaa ttttcagata aaaatgaaat aagagttgga aataatttg ccatggaat 19740
 caatctaaat gccaaactgt ggagaaattt cctgtactcc aacatagcg tgtatttgcc 19800
 cgacaagcta aagtacagtc ctccaacgt aaaaatttct gataaccaa acacctaga 19860
 ctacatgaac aagcgagtgg tggctcccg gctagtggac tgctacatta acctggagc 19920
 acgtgggtcc ctgactata tggacaacgt caaccattt aaccaccacc gcaatgctgg 19980
 cctgcgctac cgctcaatgt tgctgggcaa tggctgctat gtgccctcc acatccaggt 20040
 gcctcagaag ttcttgcca ttaaaaacct ctttctctg ccgggctcat acacctaga 20100
 gtggaacttc aggaaggatg ttaacatggt tctgcagagc tccctaggaa atgacctaag 20160
 ggttgacgga gccagcatta agtttgatag catttgcct tacgccact tcttcccat 20220
 ggcccacaac accgcctcca cgcttgaggc catgcttaga aacgacacca acgaccagtc 20280

cttaacgac tatctctccg ccgccaacat gctctaccct ataccgcga acgctacca 20340
 cgtgccata tccatcccct ccgcgaactg ggcggctttc cgcggctggg ccttcacgcg 20400
 ccttaagact aaggaaaccc catcactggg ctccggctac gacccttatt acactactc 20460
 tggctctata cctacctag atggaacctt ttacctcaac cacacctta agaagggtggc 20520
 cattaccttt gactcttctg tcagctggcc tggcaatgac cgcctgctta cccccaacga 20580
 gtttgaatt aagcgtcag ttgacgggga ggggtacaac gttgccagt gtaacatgac 20640
 caaagactgg ttctggtag aaatgctagc taactataac attggctacc agggcttcta 20700
 tatcccagag agctacaagg accgcatgta ctcttcttt agaaacttcc agcccatgag 20760
 ccgtcaggtg gtggatgata ctataataa ggactacca caggtgggca tctacacca 20820
 acacaacaac ctggatttg ttggctacct tccccacc atgcgcgaag gacaggccta 20880
 ccttgtaac ttccctatc cgttatagg caagaccgca gttgacgca ttaccagaa 20940
 aaagtttctt tgcgatcga cctttggcg catccattc tccagtaact ttatgtccat 21000
 gggcgcactc acagacctgg gccaaaacct tctctagcc aactccgcc acgcgctaga 21060
 catgactttt gaggtggatc ccatggacga gccaccctt ctttatgtt tgttgaagt 21120
 ctttgacgtg gtcctgtgc accagccgca ccgcggcgtc atcgaaccg tgtacctgcg 21180
 cacgcccttc tcggccggca agccacaac ataaagaagc aagcaacatc aacaacagct 21240
 gccgccatgg gctccagtga gcaggaactg aaagccattg tcaagatct tgggtgtggg 21300
 ccatattttt tgggcacctg tgacaagcgc ttccaggct tgtttctcc acacaagctc 21360
 gcctgcgcca tagtcaatc ggccggtcgc gagactgggg gcgtacactg gatggcctt 21420
 gcctggaacc cgcactcaa aacatgctac ctcttgagc ccttggctt ttctgaccag 21480
 cgactcaagc aggtttacca gtttgagtac gactcactcc tgcgcgtag cgccattgct 21540
 tcttcccccg accgtgtat aacgtggaa aagtcaccc aaagcgtaca ggggccaac 21600
 tcggccgctt gttgactatt ctgctcatg ttctccacg ccttggcaa ctggcccaa 21660
 actccatgg atcacaacc caccatgaac ctattaccg ggtacccaa ctccatgctc 21720
 aacagtcccc aggtacagcc caacctgct cgcacacagg aacagctta cagcttctg 21780
 gagegcact cgcctactt ccgcagcac agtgcgcaga ttaggagcgc cacttcttt 21840
 tgtcacttga aaaacatga aaaataatg actagagaca cttcaataa aggcacatgc 21900
 tttattttgt acactctcg gtgattatt accccaccc ttgcgtctg cgcggttaa 21960
 aatcaaaagg ggttctgctg cgcacgcta tgcgcactg gcaggacac gttgcgatac 22020
 tgggtgttag tgcctactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt 22080
 tcactccaca ggtcgcgac catccaac gcgttagca ggtcgggcgc gatatcttg 22140
 aagtcgagc tggggcctcc gccctgcgc cgcgagttgc gatacacagg gttgcagcac 22200
 tggaaacta tcagcgccgg gtggtgcacg ctggccagca cgtcttctg ggagatcaga 22260
 tccgctcca ggtctccgc gttgctcagg gcgaacggag tcaactttg tagctgcctt 22320
 cccaaaaagg gcgcgtgccc aggtttgag ttgactcgc accgtagtgg catcaaaagg 22380
 tgaccgtgcc cggctgggc gttaggatac agcgcctgca taaaagcctt gatctgcta 22440
 aaagccacct gagcctttgc gccttcagag aagaacatgc cgcaagact gccggaaaac 22500
 tgattggcg gacaggccgc gtcgtgcacg cagcacttg cgtcgggtgt ggagatctgc 22560
 accacattc ggccccaccg gttcttcacg atctggcct tgctagactg ctcttcagc 22620
 gcgcgctgcc cgtttgcct cgtcacatcc attcaatac cgtgctcctt atttatcata 22680
 atgcttccgt gtagacatt aagctcgcct tcgatctcag cgcagcgtg cagccacaac 22740
 gcgcagccc tgggctcgtg atgctgtag gtcaccttg caaacgactg caggtagcc 22800
 tgcaggatc gcccatcat cgtcacaag gtctgttgc tggtaaggt cagctgcaac 22860
 ccgcggtgct cctcgttcag ccaggtctg catagggcg ccagagcttc cacttggtca 22920
 ggtagtagtt tgaagttcgc cttagatcg ttatccagt ggtacttgc catcagcgc 22980
 cgcgcagcct ccatgccctt cccccagca gacacgatc gcacactcag cgggttcac 23040
 accgtaatt cacttccgc ttgctgggc tcttctctt cctctgcgt ccgcataca 23100
 cgcgccactg ggtcgtcttc attcagcgc cgcactgtc gcttacctc ttgcatgc 23160
 ttgattaga ccggtgggtt gctgaaccc accatttga gcgccacatc ttcttctt 23220
 tctcgtctg ccacgattac ctctggtgat ggcgggcgt cgggttggg agaagggcg 23280

tttttttt tcttgggctc aatggccaaa tccgccgccc aggtcgatgg ccgagggtg 23340
 ggtgtgcgcg gcaccagcgc gtcttgtat ggtcttctc cgtctcggg ctcgatacgc 23400
 cgcctcatcc gcttttttgg gggcgcccgg ggaggcggcg gcgacgggga cggggacgac 23460
 acgtcctcca tgggtggggg acgtcgcgc gcaccgcgtc cgcgtcggg ggtggtttcg 23520
 cgtgctctc tttcccact ggccatttc tctcctata ggcaaaaa gatcatggag 23580
 tcagtgcaga agaaggacag cctaaccgcc cctctgagt tcgccaccac cgcctccacc 23640
 gatgcccca acgcgcctac cactttccc gtcaggcac cccgcttga ggaggaggaa 23700
 gtgattatcg agcaggaccc aggttttga agcgaagacg acgaggaccg ctcatgacca 23760
 acagaggata aaaagcaaga ccaggacaac gcagaggcaa acgaggaaca agtcggggcg 23820
 ggggacgaaa ggcatggcga ctacctagat gtgggagacg acgtgctgtt gaagcatctg 23880
 cagcgccagt gcgccattat ctgcgacgc ttgcaagagc gcagcgatgt gccctcgc 23940
 atagcggatg tcagccttgc ctacgaacgc cactattct caccgcgct acccccaaa 24000
 cgcaagaaa acggcacatg cgagcccaac ccgcgcctca acttctacc cgtatttgc 24060
 gtccagagg tgcctgccac ctatcacatc ttttccaa actgcaagat accctatcc 24120
 tgcctgccac accgcagccc agcggacaag cagctggcct tgcggcaggg cgtgtcata 24180
 cctgatatcg cctcgtcaa cgaagtcca aaaatcttg aggtcttgg acgcgacgag 24240
 aagcgcgcgg caaacgctct gcaacaggaa aacagcgaat atgaaagta ctctggatg 24300
 ttggtggaac tcgagggtga caacgcgcgc ctgaccgtac taaaacgcag catcgaggtc 24360
 accactttg cctaccggc acttaacct cccccaagg tcatgagcac agtcatgagt 24420
 gagctgatcg tgcgcgtgc gcagcccctg gagagggatg caatttga agaacaaca 24480
 gaggaggcc taccgcagt tggcgacgag cagctagcgc gctggctca aacgcgcgag 24540
 cctgcgact tggaggagcg acgcaacta atgatggccg cagtgtcgt taccgtggag 24600
 ctgagtga tgcagcgtt cttgtctgac ccgagatgc agcgcaagct agaggaaaca 24660
 ttgactaca ctttgcga ggcctacgta cgcaggcct gcaagatct caacgtggag 24720
 ctctgaacc tggctccta ctttgaatt ttgcagaa accgcttgg gcaaacgtg 24780
 ctctatcca cgtcaaggg cgaggcgcgc cgcactacg tcgcgactg cgttactta 24840
 ttctatgct acactggca gacggcatg ggcgttggc agcagtgtt ggaggagtgc 24900
 aacctagg agctgcagaa actgctaaag caaaactga aggacatg gacggcctc 24960
 aacgagcgt cgtggccgc gcactggcg gacatctt tcccgaacg cgtcttaa 25020
 accctgaac aggtctgccc agacttacc agtcaagca tgttcagaa ctttagaac 25080
 ttatctag agcgtcagg aatctgccc gccactgct gtgacttcc tagcactt 25140
 gtgcccata agtaccgca atgcccctc cgttttggg gccactgta cttctgcag 25200
 ctgccaact acctgcta cactctgac ataaggaag acgtgagcgg tgacgttca 25260
 ctggagtgc actgtcgtc caacctatgc acccgacc gctccctgt ttgcaattc 25320
 cagctgcta acgaaagta aattatcgt accttgagc tgcagggtcc ctgcctgac 25380
 gaaaagtcg cggctccggg gttgaaact actccgggc tgtggacgt ggcttacct 25440
 cgcaatttg tactgagga ctaccagcc cagagatta ggttctaca agaccaatcc 25500
 cggccgcta atgaggagt taccgctgc gtcattacc agggcccat tcttgccaa 25560
 ttgcaagca tcaaaaagc ccgcaagag tttctgtac gaaaggagc gggggttac 25620
 ttgaccccc agtccggca ggagctaac caatcccc cgcgcgcga gccctatcag 25680
 cagcagccc gggcccttgc ttccaggat ggcacccaa aagaagctgc agtgcgcc 25740
 gccaccacg gacgaggagg aatactgga cagtaggca gaggaggtt tggacagga 25800
 ggaggaggac atgatggaag actggagag ctagacgag gaagcttcc aggtcgaaga 25860
 ggtgtcagac gaaacacgt caccctcgt cgttcccc tcgccggcg cccagaaatc 25920
 ggcaaccgt tccagatgg ctacaacct cgtctctag gcgccggg cactgccgt 25980
 tcgccgcc aaccgtatg gggacaccac tgaaccagg gccgtaagt ccaagcagcc 26040
 gccgccgtt gcccaagagc aacaacgcg ccaaggctac cgtcatggc gcgggcaca 26100
 gaagccata gtgtctgt tgcaagactg tgggggcaac atctcttcg ccgcccgtt 26160
 tcttctac catcacgcg tggcctccc cgtaacatc ctgattact accgtatct 26220
 ctacagcca tactgaccg gcggcagcg cagcaacagc agcgccaca cagaagcaa 26280

ggcgaccgga tagcaagact ctgacaaagc ccaagaaatc cacagcgcg gcagcagcag 26340
 gaggaggagc gctgcgtctg gcgcccacg aaccggtatc gacccgcgag cttagaaaca 26400
 ggatttttcc cactctgtat gctatattc aacagagcag gggccaagaa caagagctga 26460
 aaataaaaaa caggctctctg cgatccctca cccgcagctg cctgtatcac aaaagcgaag 26520
 atcagcttcg gcgcagcctg gaagacgcgg aggcctctct cagtaaatc tgcgcgctga 26580
 ctctaagga ctagtctgc gccctttctc aaattiaagc gcgaaaacta cgtcatctcc 26640
 agcggccaca cccggcgcca gcacctgttg tcagcgccat tatgagcaag gaaattcca 26700
 cgccctacat gtggagttac cagccacaaa tgggacttgc ggctggagct gcccaagact 26760
 actcaaccg aataaactac atgagcgcg gcacccacat gatatcccg gtcaacggaa 26820
 tacgcgcccc ccgaaaccga attctctgg aacaggcggc tattaccacc acacctcgt 26880
 ataacttaa tccccgtagt tggcccgctg ccctgggtga ccaggaaagt cccgctcca 26940
 ccactgtgtt acttccaga gacgccagg ccgaagtta gatgactaac tcaggggcgc 27000
 agcttgcggg cggcttctgt cacagggtgc ggtcgcccg gcagggtata actcactga 27060
 caatcagagg gcgaggtatt cagctcaacg acgagtcggt gagctcctcg ctggctctcc 27120
 gtccggacgg gacatttcag atcgcgcg cgcgccgctc ttattcacg cctcgtcagg 27180
 caatcctaac tctgcagacc tctctctg agccgcgctc tggaggcatt ggaactctg 27240
 aattattga ggagtttg ccacgggtct acttaacc cttctcgga cctcccgcc 27300
 actatccgga tcaatttatt cctaacttg acgcggtaaa ggactcggcg gacggctacg 27360
 actgaatgtt ataagtctt gtccatccg accactatc ttcatgtgt tgcagatgaa 27420
 gcgcgcaaga ccgtctgaag atacctcaa ccccggtat ccatatgaca cggaaccgg 27480
 tctccaact gtgcctttt ttactctcc cttgtatcc ccaatgggt ttcaagagag 27540
 tccccctggg gtactctct tgcgctatc cgaacctta gttacctca atggcatgt 27600
 tgcgtcaaaa atgggcaacg gcctctctt ggacgaggcc ggcaacctta cctccaaaa 27660
 tgaaccact gtgagccac ctctcaaaa aaccaagca acaataaac tggaaatct 27720
 tgcacccctc acagttaact cagaagccct aactgtggt gcgcgcac cttaatggt 27780
 cgcgggcaac acatcaaca tgcataca ggccccga accgtgcag actcaaac 27840
 tagcattgcc accaaggac cctcacagt gtcagaagga aagctagccc tgcatacat 27900
 agccccctc accaccag atagcagtc cttactatc actgcctac cctctaac 27960
 tactgccact ggtagcttg gattgactt gaaagagccc atttatac aaaatgaaa 28020
 actaggacta aagtacgggg ctctttgca tgaacagac gacctaaaca cttgaccgt 28080
 agcaactggt ccagggtgta ctattaata tacttccttg caaactaaag ttactggagc 28140
 ctgggtttt gattcacaag gcaatatga actaatgta gcaggaggac taaggattga 28200
 ttctcaaac agacgcctta tacttgatgt tagttatccg ttgatgctc aaaaccaact 28260
 aaatctaaga ctaggacagg gccctcttt tataaactca gcccaact tggatattaa 28320
 ctacaacaaa ggcctttact tgttacagc ttcaacaat tcaaaaagc ttgaggttaa 28380
 cctaagcact gccagggggt tgatgttga cgctacagcc atagccatta atgcaggaga 28440
 tgggcttgaa ttggttcac ctaatgcacc aaacacaaat cccctcaaaa caaaaattgg 28500
 ccatggccta gaatttgatt caaacaaggc tatggttctt aaactaggaa ctggccttag 28560
 tttgacagc acagggtcca ttacagtagg aaacaaaaat atgataagc taactttgtg 28620
 gaccacacca gctcatctc ctaactgtag actaatgca gagaagatg ctaaactcac 28680
 ttgtgtcta acaaatgtg gcagtcfaat acttgctaca gttcagttt tggctgttaa 28740
 aggcagtttg gctccaatat ctggaacagt tcaaagtgt catctatta taagattga 28800
 cgaaaatgga gtgctactaa acaattcct cctggacca gaatttgga acttagaaa 28860
 tggagatctt actgaaggca cagctatc aaacgctgtt ggatttatgc ctacctatc 28920
 agcttatcca aaatctcac gtaaaactgc caaaagtaac attgtcagtc aagttactt 28980
 aaacggagac aaactaaac ctgtaacact aaccattaca ctacacgga cacaggaaac 29040
 aggagacaca actccaagt cactctat gtcatttca tgggactggt ctggccaca 29100
 ctacattaat gaaatattg ccacatctc ttacatttt tcatattg cccaagaata 29160
 aagaatcgtt tgtgtatgt ttcaactgt ttattttca attgcagaaa attcaagtc 29220
 attttcatt cagtagtata gcccaccac cacatagctt atcagatca ccgtacctt 29280

atcaaaactca cagaacccta gtattcaacc tgccacctcc ctcccaacac acagagtaca 29340
 cagtcctttc tccccggctg gccttaaaaa gcatcatatc atgggtaaca gacatatct 29400
 taggtgttat attccacag gtttctgtc gagccaaacg ctcatcagtg atattaataa 29460
 actccccggg cagctcactt aagttcatgt cgtgtccag ctgctgagcc acaggctgct 29520
 gtccaacttg cgggtgctta acgggcggtg aaggagaagt ccacgcctac atgggggtag 29580
 agtcataatc gtgcatcagg atagggcggt ggtgctgcag cagcgcgcga ataaactgct 29640
 gccgcccggc ctccgtctg caggaataca acatggcagt ggtctcctca gcgatgattc 29700
 gcaccgcccg cagcataagg cgccttgctc tccgggcaca gcagcgacc ctgatctcac 29760
 ttaaatcagc acagtaactg cagcacagca ccacaatatt gttcaaaac ccacagtga 29820
 aggcgctgta tccaaagctc atggcgggga ccacagaacc cagtggtcca tcataccaca 29880
 agcgaggga gattaagtgg cgacccctca taaacacgct ggacataaac attacctct 29940
 ttggcatgtt gtaattcacc acctccggg accatataaa cctctgatta aacatggcg 30000
 catccaccac catcctaaac cagtggtcca aaacctgccc gccggctata cactgcaggg 30060
 aaccgggact ggaacaatga cagtggagag cccaggactc gtaaccatgg atcatcatg 30120
 tcgtcatgat atcaatgttg gcacaacaca ggacacgtg cataacttc ctaggatta 30180
 caagctctc ccggttaga accatatccc agggaaacac ccattctga atcagcgtaa 30240
 atccacact gcagggaaga cctgcacgt aactcacgtt gtgattgtc aaagtgtac 30300
 attcgggag cagcgatga tctccagta tggtagcgcg ggtttctgtc taaaaggag 30360
 gtagcagtc cctactgtac ggagtgccc gagacaaccg agatcgtgtt ggtcgtagt 30420
 tcatacaaa tggaaacggc gacgtagtca tattctga agcaaaacca ggtgcggcg 30480
 tgacaacag atctgcgtc cgggtctgc cgttagatc gctctgtga gtagtgtag 30540
 tataccact ctctaaagc atccaggcg cccctggctt cgggttctat gtaactcct 30600
 tcatgcgcg ctgcctgat aacatccacc accgcagaat aagcacacc cagccaact 30660
 acacattct tctcgagtc acacacggga ggagcggga gagctggaag aacctgtt 30720
 tttttttat tccaaaagat tatccaaac ctcaaatga agatctatta agtgaacgc 30780
 ctccctcgc gtggcgtgtt caactctac agccaaagaa cagataatgg catttgaag 30840
 atgtgcaca atggctcca aaaggcaac ggccctcacg tccaagtga cgtaaaggct 30900
 aaaccttca gggatgaatc cctctataaa cattccagca cttcaacca tgcccaata 30960
 attctatct cgccacctc tcaatatac tctaagcaaa tcccgaatat taagtccggc 31020
 cattgtaaa atctgtcca gagcgccctc cacttcagc ctcaagcagc gaatcatgat 31080
 tgcaaaaatt caggttctc acagacctgt ataagattca aaagcgaac attaacaata 31140
 ataccgcag cccgtaggtc cttcgcagg gccagctgaa cataatcgtg caggctgca 31200
 cggaccagc cggccactc cccgccagg accatgacaa aagaaccac actgattatg 31260
 acacgcatac tcggagctat gtaaccagc gtagccccga tgtaagcttg ttgatggg 31320
 ggcgatataa aatgcaagg gctgtcaaa aatcaggca aagcctcgc caaaaagaa 31380
 agcacatcgt agtcatgctc atgcagataa aggcaggtaa gctccgaac caccacagaa 31440
 aaagacacca ttttcttc aaacatgtc gcgggtttc gcataaacac aaaataaat 31500
 aacaaaaaa catttaaca ttagaagcct gtctacaac aggaataaca accctataa 31560
 gcataagac gactacggc atgccggct gaccgtaaaa aaactggtc cgtgattaa 31620
 aaagcaccac gcagagctc tcggtcatgt cggagtcac aatgtaagac tcggtataa 31680
 catcagggtg attcacatc gtcagtgtc aaaaagcagc gaaatagccc gggggaatac 31740
 ataccgcag gcgtagagc aacattacg ccccatagg aggtataca aaattaatag 31800
 gagagaaaaa cacataaca cctgaaaaa cctcctgct aggcataata gcaccctcc 31860
 gctccagaac aacatacag gttccacag cggcagcat aacagtcagc ctaccagta 31920
 aaaaagaaaa cctattaaaa aacaccact gcacagga ccagctcaat cagtcacag 31980
 gtaaaaaagg gccaaagtca gagcgagt atataggact aaaaaatgac gtaacggtta 32040
 aagtcacaa aaacaccca gaaaaccga cgcgaaccta cggcagaaa cgaaagcaa 32100
 aaaaccaca acttctcaa atcgtcact cgttttccc acgttacgc acttccatt 32160
 ttaagaaaac tacaattccc aacacatac agttactcc cctaaacc tacgtaccc 32220
 gcccggttc cagcggcgc gccacgtcac aaactccacc cctcattat catattggc 32280

tcaatccaaa ataaggata ttattgatga tgttacatcg ttaattaacg atttgaacc 32340
 cggggtagcg aattcctcga gtctagagga gcatgcgacg tcgcaattcg ccctatagt 32400
 agtcgtatta caattcactg gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg 32460
 ttaccaact taatcgctt gcagcacatc ccccttcgc cagctggcgt aatagcgaag 32520
 aggcccgac cgatcgccct tcccaacagt tgcgcagcct gaatggcgaa tggaaattgt 32580
 aagcgtaat attttgttaa aattcgctt aaattttgt taaatcagct catttttaa 32640
 ccaataggcc gaaatcggca aaatcccta taaatcaaaa gaatagaccg agatagggtt 32700
 gagtgttgtt ccagtttga acaagagtc actattaaag aacgtggact ccaacgtcaa 32760
 agggcgaaaa accgtctatc agggcgatgg cccactacgt gaaccatcac cctaataag 32820
 tttttgggg tcgagggtcc gtaaagcact aaatcggaac ctaaaggga gcccccgtt 32880
 tagagctga cggggaaagc cggcgaaagt ggcgagaaag gaagggaaga aagcgaagg 32940
 agcggcgct agggcgctgg caagtgtagc ggtcacgtcg cgcgtaacca ccacccgc 33000
 cgcgctaat gcgccgtac agggcgctc ctgatcggt attttctct tacgcatctg 33060
 tgcggtatt cacaccgat acaggtggca ctttcgggg aaatgtgcgc ggaacccta 33120
 ttgtttatt ttctaaata cattcaata tgtatccgct catgagaaa taacctgat 33180
 aaatgctca ataattga aaaagggaaga gtatgagtat tcaacatttc cgtgtcgccc 33240
 ttattccctt ttgtcgga tttgccttc ctgttttgc tcaccagaa acgctggtga 33300
 aagtaaaaga tgcgaagat cagttgggtg cagagtggtt ttacatcga ctggatctca 33360
 acagcggtaa gatccctgag agttttgcc ccgaagaacg tttccaatg atgacactt 33420
 ttaaagtct gctatgtgc gcgtattat cccgtattga cgcgggcaa gagcaactcg 33480
 gtcgccgat acactattct cagaatgact tggttgagta ctaccagtc acagaaaagc 33540
 atcttargga tgcctgaca gtaagagaat tatecagtc tgcataacc atgagtata 33600
 acactgcgc caactactt ctgacaacga tcggaggacc gaaggagcta accgttttt 33660
 tgcacaatc ggggatcat gtaactgcc ttgatcttg ggaaccggag ctgaatgaag 33720
 ccatacaaa cgacgagct gacacacga tgcctgtagc aatggcaaca acgttgcca 33780
 aactattaac tggcgaacta ctactctag ctcccgga acaattaata gactggatgg 33840
 aggcggataa agttgcagga ccactctgc gctcgccct tcggctggc tggttattg 33900
 ctgataaat tggagccgt gagcgtgggt ctgcgggtat cattgcagca ctggggccag 33960
 atgtaagcc ctccgtatc gtatgtatct acacgacggg gactcaggca actatggatg 34020
 aacgaatag acagatcgt gagatagggt cctcactgat taagcattgg taactgtcag 34080
 accaagtta ctatata cttagattg atttaaaact tcatttttaa tttaaaagga 34140
 tctaggtaga gatcctttt gataatcra tgacaaaaat cccttaacgt gagttttcgt 34200
 tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgatg ctttttttc 34260
 tgcgctaag ctgctgttg caaacaacaa aaccaccgt accagcgggt gttttttgc 34320
 cggatcaaga gctaccaact cttttccga aggtactgg ctccagcaga gcgcagatac 34380
 caaatactgt tcttctagt tagccgtagt taggccacca ctcaagaac tctgtagcac 34440
 cgctacata cctcgtctg ctaatcctgt taccagtggc tgcgccagt ggcgataagt 34500
 cgtgtctac cgggttggc tcaagacgat agttaccgga taaggcgag cggtcgggt 34560
 gaacgggggg ttctgcaca cagcccagct tggagcgaac gacctacac gaactgagat 34620
 acctacagc tgagctatga gaaagcgcca cgctccga agggagaaag gcggacaggt 34680
 atccgtaag cggcagggc ggaacaggag agcgacagag ggagcttcca gggggaaagc 34740
 cctggtatct ttatgtct gtcgggttc gccacctctg acttgagcgt cgattttgt 34800
 gatgtctgc agggggcg agcctatgga aaaacgccag caacgcggcc tttttacgt 34860
 tctggcctt ttgtggcct ttgtctaca tgttcttcc tgcgttatcc cctgattctg 34920
 tggataaccg tattaccgcc ttgagttag ctgataccgc tcgccgagc cgaacgaccg 34980
 agcgacgca gtcagttagc gaggaagcgg aagagcgccc aatacgaaa ccgctctcc 35040
 ccgcgcttg gccattcat taatgcagct ggcacgacag gttcccgac tggaaagcgg 35100
 gcagttagcg caacgaatt aatgtgagt agtcaacta ttaggccacc caggctttac 35160
 actttatgt tccggctcgt atgtgtgtg gaattgtgag cggataacaa tttcacag 35220
 gaaacagcta tgaccatgat tacgccaagc tatttaggtg aactataga atactcaagc 35280

1340-IP.WorkFile

tagttaatta acgttaatta acatcatcaa taatatacct tattttggat tgaagccaat 35340
atgataatga ggggggtggag ttgtgacgt ggcgcggggc gtgggaacgg ggcgggtgac 35400
gtagtagtgt ggcggaagtg tgatgttgca agtgtggcgg aacacatgta agcgacggat 35460
gtggcaaaag tgacgttttt ggtgtgcgcc ggtgtacaca ggaagtgaca attttcgcgc 35520
ggttttaggc ggatgttgta gtaatttgg gcgtaaccga gtaagatttg gccattttcg 35580
cgggaaaact gaataagagg aagtgaatc tgaataattt tgtgttactc atagcgcgta 35640
atctctagca t 35651

<212> Type : DNA

<211> Length : 35651

SequenceName : SEQ ID No.1

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID No.1

REFERENCES

1. Andersen, M. M. and T. Ronne. 1991. Side-effects with Japanese encephalitis vaccine. *Lancet* 337:1044.
2. Ashok, M. S. and P. N. Rangarajan. 2000. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. *Vaccine* 18:68-75.
3. Both, G. W., L. J. Lockett, V. Janardhana, S. J. Edwards, A. R. Bellamy, F. L. Graham, L. Prevec, and M. E. Andrew. 1993. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. *Virology* 193:940-950.
4. Casimiro, D. R., A. Tang, L. Chen, T. M. Fu, R. K. Evans, M. E. Davies, D. C. Freed, W. Hurni, J. M. Aste-Amezaga, L. Guan, R. Long, L. Huang, V. Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy, K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol.* 77:7663-7668.
5. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression and replication. *Annu. Rev. Microbiol.* 44:649.
6. Chang, G.-J. J., A. R. Hunt, and B. Davis. 2000. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. *Journal of Virology* 74:4244-4252.
7. Chen, H. W., C. H. Pan, M. Y. Liao, R. Jou, C. J. Tsai, H. J. Wu, Y. L. Lin, and M. H. Tao. 1999. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. *J. Virol.* 73:10137-10145.
8. Chengalvala, M. V., B. M. Bhat, R. A. Bhat, S. K. Dheer, M. D. Lubeck, R. H. Purcell, and K. K. Murthy. 1997. Replication and immunogenicity of Ad7-

- Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. *Vaccine* 15:335-339.
9. **Flanagan, B., C. R. Pringle, and K. N. Leppard.** 1997. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. *J Gen. Virol.* 78 (Pt 5):991-997.
 10. **Fonseca, B. A., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason.** 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. *Vaccine* 12:279-285.
 11. **Fooks, A. R., D. Jeevarajah, J. Lee, A. Warnes, S. Niewiesk, M. ter, V, J. R. Stephenson, and J. C. Clegg.** 1998. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. *J Gen. Virol.* 79 (Pt 5):1027-1031.
 12. **Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath.** 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. *J Virol.* 74:5477-5485.
 13. **Imler J.L.** 1995. Adenovirus vectors as recombinant viral vaccines. *Vaccine* 13:1143-1151.
 14. **Jan, L. R., C. S. Yang, L. S. Henchal, H. Sumiyoshi, P. L. Summers, D. R. Dubois, and C. J. Lai.** 1993. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. *Am. J Trop. Med. Hyg.* 48:412-423.
 15. **Kaur, R., G. Sachdeva, and S. Vрати.** 2002. Plasmid DNA immunization against Japanese Encephalitis Virus: immunogenicity of membrane-anchored and secretory envelope protein. *J. Infect. Dis.* 185:1-12.
 16. **Kaur, R. and S. Vрати.** 2003. Development of a recombinant vaccine against Japanese encephalitis. *J Neurovirol* 9:421-431.
 17. **Kimura-Kiroda, J. and K. Yasui.** 1988. Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies. *J. Immunol.* 141:3606-3610.
 18. **Konishi, E., S. Pincus, E. Paoletti, R. E. Shope, T. Burrage, and P. W. Mason.** 1992. Mice immunized with a subviral particle containing the Japanese

- encephalitis virus prM/M and E proteins are protected from lethal JEV infection. *Virology* **188**:714-720.
19. **Konishi, E., M. Yamaoka, S. W. Khin, I. Kurane, K. Takada, and P. W. Mason.** 1999. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. *J. Virol.* **73**:5527-5534.
 20. **Konishi, E., M. Yamaoka, Khin-Sane-Win, I. Kurane, and Mason P.W.** 1998. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. *Journal of Virology* **72**:4925-4930.
 21. **Lemiale, F., W. P. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel.** 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. *J Virol.* **77**:10078-10087.
 22. **Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright.** 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. *Virology* **202**:885-890.
 23. **Livingston, P. G., I. Kurane, C. J. Lai, M. Bray, and F. A. Ennis.** 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones. *J Virol.* **68**:3283-3288.
 24. **Lubeck, M. D., A. R. Davis, M. Chengalvala, R. J. Natuk, J. E. Morin, K. Molnar-Kimber, B. B. Mason, B. M. Bhat, S. Mizutani, P. P. Hung, and .** 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. *Proc. Natl. Acad. Sci. U. S. A* **86**:6763-6767.
 25. **Mason P.W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti.** 1991. Japanese encephalitis virus-Vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. *Virology* **180**:294-305.
 26. **McMinn, P. C.** 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. *J Gen. Virol.* **78 (Pt 11)**:2711-2722.

27. **Men, R., M. Bray, and C.-J. Lai.** 1991. Carboxy-terminal truncated dengue virus envelope glycoprotein expressed on the cell surface and secreted intracellularly exhibit increased immunogenicity in mice. *Journal of Virology* **65**:1400-1407.
28. **Monath, T. P.** 2001. Prospects for development of a vaccine against the West Nile virus. *Ann. N. Y. Acad. Sci.* **951**:1-12.
29. **Monath, T. P.** 2002. Japanese encephalitis vaccines: current vaccines and future prospects. *Curr. Top. Microbiol. Immunol.* **267**:105-138.
30. **Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo.** 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. *Vaccine* **20**:1004-1018.
31. **Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo.** 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. *Vaccine* **17**:1869-1882.
32. **Pan, C. H., H. W. Chen, H. W. Huang, and M. H. Tao.** 2001. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. *J Virol.* **75**:11457-11463.
33. **Plesner, A. M. and T. Ronne.** 1997. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. *Vaccine* **15**:1239-1243.
34. **Putnak, R., R. Feighny, J. Burrous, M. Cochran, C. Hackett, G. Smith, and C. Hoke.** 1991. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. *Am. J Trop. Med. Hyg.* **45**:159-167.
35. **Raikwar, S. P., P. Malik, O. Singh, and S. Vрати.** 1997. Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bionutralizing antibodies in rats. *Gene* **190**:197-202.
36. **Ramakrishna, C., A. Desai, S. K. Shankar, A. Chandramuki, and V. Ravi.** 1999. Oral immunisation of mice with live Japanese encephalitis virus induces a protective immune response. *Vaccine* **17**:3102-3108.

37. **Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter.** 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. *Vaccine* 18:2426-2434.
38. **Ruff, T. A., D. Eisen, A. Fuller, and R. Kas.** 1991. Adverse reactions to Japanese encephalitis vaccine. *Lancet* 338:881-882.
39. **Sakaguchi, M., M. Yoshida, W. Kuroda, O. Harayama, Y. Matsunaga, and S. Inouye.** 2000. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. *Vaccine* 15:121-122.
40. **Sharpe, S., A. Fooks, J. Lee, K. Hayes, C. Clegg, and M. Cranage.** 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. *Virology* 293:210-216.
41. **Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini.** 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature* 415:331-335.
42. **Vos, A., A. Neubert, E. Pommerening, T. Muller, L. Dohner, L. Neubert, and K. Hughes.** 2001. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. *J Gen. Virol.* 82:2191-2197.
43. **Vrati, S., V. Agarwal, P. Malik, S. A. Wani, and M. Saini.** 1999. Molecular characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. *J. Gen. Virol.* 80:1665-1671.

44. **Vrati, S., R. K. Giri, A. Razdan, and P. Malik.** 1999. Complete nucleotide sequence of an Indian strain of Japanese encephalitis virus: sequence comparison with other strains and phylogenetic analysis. *Am. J. Trop. Med. Hyg.* **61**:677-680.
45. **World Health Organization.** 1998. Japanese encephalitis vaccines. *Wkly. Epidemiol Rec* **73**:334-344.
46. **Xiang, Z., Y. Li, G. Gao, J. M. Wilson, and H. C. Ertl.** 2003. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. *J Immunol.* **171**:4287-4293.
47. **Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl.** 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. *J Virol.* **77**:10780-10789.
48. **Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl.** 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* **219**:220-227.
49. **Yoshida, T., K. Okuda, K. Q. Xin, K. Tadokoro, J. Fukushima, S. Toda, E. Hagiwara, K. Hamajima, T. Koshino, and T. Saito.** 2001. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. *Clin. Exp. Immunol.* **124**:445-452.
50. **Zhao, J., Y. Lou, J. Pinczewski, N. Malkevitch, K. Aldrich, V. S. Kalyanaraman, D. Venzon, B. Peng, L. J. Patterson, Y. Edghill-Smith, R. Woodward, G. N. Pavlakis, and M. Robert-Guroff.** 2003. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. *Vaccine* **21**:4022-4035.


We Claim:

1. A method of preparing a recombinant adenovirus (RAdEs) vaccine - The Accession Number 04121701 - to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein (Es) of JEV, said method comprising steps of:
 - a. digesting plasmid pMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding JEV proteins prM and Es,
 - b. ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
 - c. filling nucleotides at the free *Bam* HI and *Hind* III ends with T4 DNA polymerase to create blunt ends,
 - d. ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,
 - e. digesting the shuttle plasmid pSEs with restriction enzymes I-*Ceu* I and PI-*Sce* I to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
 - f. ligating the digested shuttle plasmid with I-*Ceu* I and PI-*Sce* I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing Es expression cassette,
 - g. digesting the plasmid pAdEs with *Pac* I,
 - h. transfecting the monolayers HEK 293 cells with digested plasmid pAdEs for about one week, and
 - i. obtaining the recombinant virus RAdEs vaccine. The Accession Number 04121701.
2. A method as claimed in claim 1, wherein the transfection is at about 37°C temperature.
3. A method as claimed in claim 1, wherein the JEV proteins are under the control of human CMV IE promoter/enhancer.
4. A recombinant adenovirus (RAdEs) vaccine, the Accession Number 04121701, optionally along with pharmaceutically acceptable additives.
5. A vaccine as claimed in claim 4, wherein the vaccine produces secretory envelope protein of JEV.

6. A vaccine as claimed in claim 4, wherein the vaccine protects against Japanese encephalitis virus (JEV) infection.
7. A vaccine as claimed in claim 4, wherein the vaccine is effective by intramuscular route of administration.
8. A vaccine as claimed in claim 4, wherein the additives are selected from a group comprising alum, gelatin and thiomersal.
9. A plasmid pAdEs of SEQ ID No: 1.
10. Use of a pharmaceutically effective amount of recombinant virus RAdEs vaccine - The Accession Number 04121701 - optionally along with additive(s) to the subject in need thereof for Japanese encephalitis virus (JEV) infection.
11. Use as claimed in claim 10, wherein the method shows 100% efficacy.
12. Use as claimed in claim 10, wherein the method helps protect subject against encephalitis.
13. Use as claimed in claim 10, wherein the subject is animal.
14. Use as claimed in claim 10, wherein the subject is a human being.
15. Use as claimed in claim 10, wherein the immunization activates both humoral and cell-mediated immune response.
16. Use as claimed in claim 10, wherein the humoral response to the vaccine comprises IgG1 type of antibody.
17. Use as claimed in claim 10, wherein the method leads to high amount of IFN-gamma secretion.
18. Use as claimed in claim 10, wherein immunization leads to moderate levels of IL-5 synthesis.
19. Use as claimed in claim 10, wherein increased amount of RAdEs leads to higher immune response.
20. Use as claimed in claim 10, wherein the method is more effective than the commercially available vaccines.
21. A method of preparing a recombinant adenovirus (RAdEs) vaccine - The Accession Number 04121701 - to protect against Japanese encephalitis virus (JEV) infection substantially as herein described and illustrated therein.

22. A recombinant adenovirus (RAdEs) vaccine substantially as herein described and illustrated therein.

Dated this 1st day of December, 2004



RAVI BHOLA
OF K & S PARTNERS
AGENT FOR THE APPLICANT

ABSTRACT

The present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a method of preparing the recombinant adenovirus (RAdEs) vaccine.



FIG. 1. Growth of RADs in HEK 293A cells.




FIG. 2. Synthesis of JEV proteins in HEK 293A cells infected with RADs.




FIG. 3. Immunofluorescent staining of virus-infected cells.




FIG. 4. Antibody response in mice.




FIG. 5. Isotype analysis of anti-JEV antibody produced by immunized mice.




FIG. 6. JEV neutralizing antibody response in mice.





FIG. 7. Cytokine production by splenocytes from immunized mice.

5



50

55

60

Ravi Bhola
Ravi Bhola
of K&S Partners
Agent for the Applicant

FIG. 8. CTL activity in immunized mice




FIG. 9. Mice survival after challenge.

